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Cancer is the second leading cause of death among noncommunicable diseases coming right 
after cardiovascular diseases. Early diagnosis is a key for improving survival expectancy and 
treatment outcomes as cancer in early stage is more responsive to treatment. Currently, center of 
diseases control and prevention (CDC) recommend regular screening for cervical, breast and 
colorectal cancers. Although other screening procedures are available for prostate, pancreatic, 
thyroid and ovarian cancer, they did not prove to be effective in reducing mortality rates of these 
cancers. Adaption of prostate specific antigen (PSA) screening test for prostate cancer has not been 
related to improved survival rates instead it resulted in what has been known as “prostate cancer 
epidemic” due to overdiagnosis and overtreatment of prostate cancer.      
The dilemma of current cancer diagnostic techniques results from the tradeoff between 
specificity and sensitivity of the cancer screening. Specific cancer screening strategies that depend 
on either imaging or histopathological examination are not sensitive enough and miss latent or 
asymptomatic cancers. While sensitive techniques that depend on biomarker screening in biofluids 
like PSA test are not specific enough for accurate decision. In addition, most of these techniques 
are time consuming, expensive and require centralized laboratories with highly trained technicians. 
These criteria limit the availability of cancer screening technique to developed countries with well-
established healthcare systems and limit their application in areas with limited resources.  




The goal of this thesis is to develop and test techniques with promising specificity and 
sensitivity for screening and staging of different types of cancers. Several approaches have been 
studied to develop point-of-care (POC) sensors for prostate, head and neck cancers that are of low 
cost, utilizes low sample volumes, automated or semiautomated, and can be utilized in remote 
areas with limited resources. 3D printing was used to prototype and mass produce microfluidic 
chips and adaptors with better fluid handling characteristics and much lower cost than traditional 
microfluidic systems. Panels of selected biomarker proteins were multiplexed on the same 
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1.1 Cancer Facts  
Cancer is the second cause of death worldwide with approximately 10 million deaths expected 
in 2018. In US, approximately 1.7 million cases are diagnosed annually with more than 600,000 
deaths.1,2 Cancer screening helped improving survival rate and quality of life for many cancer 
survivors. Treatment options are more effective when cancerous lesions are small in size and did 
not metastasize to other parts of the body. FDA approved screening procedures for several types 
of cancers including colon, rectum, prostate, cervix and breast cancers which helped reduce 
mortality rate of these cancers.3,4 Adoption of screening techniques in developed countries resulted 
in early diagnosis and more cancer incidences as compared to developing world (Fig. 1.1).  
 
 
Fig. 1.  1 Estimated cancer Age-Standardized Rate (ASR) in 2018. Reproduced with permission 




Although proven to be helpful in reducing mortality rates, current diagnosis strategies results 
in overdiagnosis with patient receiving unnecessary treatment or undergoing life-threatening 
surgeries.5 The alternate route for cancer diagnosis rely on physical exams with symptoms 
presented to healthcare providers or specialists. Specialist will always request further lab works, 
CT scans and may be biopsies to confirm their findings. Even after diagnosis, staging and assessing 
treatment depends on insensitive imaging or low specificity blood work.6,7  
1.2 Cancer Biomarkers 
The use of “biomarkers” to screen, diagnose, stage and assess response of cancers to treatment 
have sparked a massive amount of research in order to develop sensitive and fast caner diagnostics 
at low cost. Biomarker in general is a molecule expressed in body fluid and can be correlated to a 
specific condition or disease 8,9 and can be proteins,10,11 RNA,12 DNA13 or small molecules. 14,15 
The change in expression level of biomarkers has been correlated to many diseases like different 
types of cancer, parkinsonism, metabolic disorders and infectious diseases. Due to the non-
invasive nature of biomarker testing, they represented excellent candidates for development of 
rapid, sensitive and cost-effective testing techniques.16  
1.3 Point-of-care (POC) testing  
Point-of-care (POC) testing refers to any testing technique that can be performed at the point 
of care which can be home, doctor’s office or remote area where conventional laboratory testing 
cannot be integrated.17 World Health Organization (WHO) Sexually Transmitted Disease 
Diagnostics Initiative specified “ASSURED” criteria for POC testing in resource-limited 
settings.18 ASSURED criteria describe the characteristics for ideal POC as follow: 
• Affordable by those at risk 




• Specific (few false-positives) 
• User-friendly (simple to perform and requiring minimal training) 
• Rapid (to enable treatment at first visit) and Robust (does not require refrigerated 
storage) 
• Equipment-free 
• Delivered to those who need it 
Current cancer diagnostics and screening rely on well-established techniques like magnetic 
resonance imaging (MRI), computed tomography (CT) scan and pathological examination. 
Although these techniques can specifically detect cancer, still they lack required sensitivity for 
early diagnosis and accurate staging of the disease resulting in late diagnosis with high rate of false 
negatives. In addition, most of these techniques require centralized laboratories with highly trained 
operators making them cost-prohibitive and inaccessible for many patients.19,20  
Recently, more sensitive tests have been proposed like prostate specific antigen (PSA) test for 
prostate cancer screening,21 Guaiac‐based fecal occult blood test (gFOBT) for colorectal cancer,22 
and Pap test and human papilloma virus (HPV) DNA test for cervical cancer.23 These tests 
promised high sensitivity for early diagnosis and staging of cancer state but suffered from low 
specificity issues. For example, PSA test resulted in what has been known as “prostate cancer 
epidemic” in USA due to overdiagnosis and unnecessary biopsies and treatment of prostate cancer 
associated with adaption of the test as an annual screening technique.24 This low specificity is 
attributed to change in the levels of expression of the selected biomarkers in conditions other than 




To overcome limitations associated with low specificities of single biomarker assay, analyzing 
several biomarkers has been suggested as an alternate approach to enhance assays clinical 
significance. Multiplexing biomarkers showed potential in improving diagnostic outcomes and 
screening for prostate cancer,25 oral cancer,26,27 breast cancer,28 lung cancer,29 ovarian cancer,30 
bladder cancer31 and colorectal cancer.32  
Development of sensitive detection techniques for protein biomarkers has been an engine for 
proposal of new cancer diagnostic strategies. Current gold standard technique for protein detection 
is enzyme linked immunosorbent assay (ELISA). ELISA has not been a very successful POC test 
due to need of bulky instruments and relatively high cost. Other techniques for protein biomarker 
quantification include LC/MS,33 protein microarrays34 and gel electrophoresis.35 Although, these 
methods promised good sensitivity and multiplexing capabilities the are still expensive and require 
bulky instruments and highly trained operators.      
1.4 Microfluidics as POC diagnostics  
Microfluidics by definition is the technique that process and manipulate small volumes of 
fluids. Microfluidics have been a workhorse for development of multiplexed protein assays 
offering the ability to achieve high sensitivity with very low amounts of samples. Inherently, 
microfluidics possesses the characteristics that qualify them for POC testing with low cost of 
production, integrated detection and ease of miniaturization for complex fluid handling. 36,37,38 In 
fact, microfluidics fulfils most of the characteristics ascribed by WHO for POC diagnostic 
techniques. Due to high surface area to volume ratio, microfluidic chambers served as an 
accelerator for immunoassay due to improved antibody-antigen interaction kinetics. This 
improved interaction helped reduce assay time from hours to minutes and improved assay 




operation and can be operated by micro pumps. Signals generated in microfluidics can be 
electrochemical, luminescence, fluorescence or colorimetric signal that can be captured and 
quantified using simple devices like Charge Coupled Detector (CCD) camera or even smartphone 
camera.40  
1.5 Microfluidic device fabrication 
Production of microfluidic devices have seen huge advances over years (Fig 1.2). The initial 
techniques for producing microfluidic systems were clean room micro-fabrication from silicon and 
glass. In 1970s, soft elastomeric micromolding chemistry was introduced and used in early 1980 
for microfluidic production.41,42 Late 1990s, Polydimethylsiloxane (PDM) leaded soft lithography 
to be the most popular technique for production of microfluidic systems due to its transparency, 
elasticity, surface characters and tendency to adsorb to glass and plastic.43 PDMS-based 
microfluidics had major limitations mainly due to its hydrophobic surface nature that prompted 
irreversible adsorption of hydrophobic molecules, incompatibility with organic solvents and 
deformability under high pressure conditions.44 PDMS-based microfluidics is still widely used as 
platform for electrochemical and chemiluminescence biosensors due to its electrochemical 





















Fig. 1.  2 Overview of the development of microfluidic manufacturing materials (grey) and 





1.6 3D printed microfluidics  
In recent years, the ability to convert computer assisted design (CAD) files into 3D-printed 
pieces, also known as additive manufacturing, has sparked significant progress in the field of 
diagnostics.45 3D printing has been utilized in a wide spectrum of applications with excellent 
design and performance. As an additive manufacturing technique, production costs are lower 
compared to traditional subtractive manufacturing techniques like milling or ablation due to 
reduction of the labor and material cost. In addition, the same 3D printer can be used to produce 
different devices and parts without the need for pre-fabrication changes usually required in 
subtractive manufacturing techniques. 46,47 These criteria make 3D printing a valuable tool in 
prototyping, testing and production of tools and equipment for analytical and diagnostic 
laboratories. In principle, CAD files of previously reported devices can be downloaded and printed 
in any laboratory, so that advanced diagnostic tools can be directly utilized by researchers without 
the need for purchase from a commercial vendor. This approach has the potential to bring advanced 
diagnostic tools more rapidly to the research lab than ever before.  
3D printed microfluidic devices have been used to fabricate semi and fully automated 
diagnostic approaches for diseases like cancer,48,49 infectious diseases,50,51,52 and xenobiotic 
genotoxicity.53 3D printing also can make tailored supporting devices that improve performance 
of existing diagnostics like spectrophotometers54 and PCR devices55 and to support smartphone 
integration for remote sensing.56,57 The ability to print materials with special properties allows for 
the creation of new equipment that can dramatically reduce the cost of diagnostic devices like 
SPR.58 All these applications used 3D printing for cost-effective multifunctional production to 




Fabrication of diagnostic devices with embedded electronics and circuits have also been 
completed by 3D printing. The ability to print different materials simultaneously permitted the 
fabrication of electrodes incorporated into insulator plastic matrices with subsequent 
electrochemical detection of metals,60,61,62 organic compounds63,64 and biologically active 
molecules.65 3D printing avoids disadvantages associated with screen printing like the need for 
masking and drying steps and allows better resolution and faster fabrication.66  
1.7 Enzyme-based signal amplification 
Construction of sandwich immunoassay structure on electrode surface has been a widely used 
approach to label captured target analytes with secondary detection antibodies which in turn are 
bounded to labeling enzyme. This approach provides higher specificity and reduce background 
noise as it does not only rely on specificity of primary antibody but also on the selectivity of the 
secondary antibodies.67 Using enzyme labels improved the sensitivity of such assays due to signal 
amplification powered by the catalytic activity of the enzyme that magnify the signal 
corresponding to one target analyte molecules hundreds of times in few seconds.68 Recently, labels 
carrying multiple enzymes have been studied to achieve ultra-high sensitivity. Previous reports 
immobilized multiple horse radish peroxidase (HRP), alkaline phosphatase (ALP) or glucose 
oxidase (GOx) on carbon nanotubes, nanoparticles, graphene or magnetic beads to amplify 
electrochemical signals.69,70,71 Degree of signal amplification is directly dependent on the enzyme 
turn over number which is “The maximal number of molecules of substrate converted to product 
per active site per unit time when the enzyme is saturated with substrate”.72 Turn over numbers for 
commonly used enzyme labels like HRP, ALP or GOx are hundreds to thousands substrate 
molecules per second. These enzymes also can be integrated with different substrates that can 




1.8 Signal transduction in microfluidic systems  
Microfluidics can be integrated with variable types of signal transduction strategies including 
electrochemical, luminescence and colorimetric techniques. The signal transform biomolecule 
analytes concentration into a measurable signal as a result of physicochemical change happening 
at sensing layer. The sensitivity of the assay will depend also on the concentration of substrate and 
its response to minute changes in the labels. Based on the signal generation strategy, microfluidics 
can be classified into electrochemical, chemiluminescence, electrochemiluminescence, 
colorimetric, fluorescence and surface plasmon resonance (SPR) systems.  
A. Electrochemical microfluidic systems 
Electrochemical microfluidic biosensors utilize a change in current, impedance, 
potential or conductance as a signal that is correlated to specific analyte concentration. In 
protein biosensors, a recognition biomolecule usually capture antibodies are immobilized 
on a conductive electrode that is maintained in contact with reference and counter 
electrodes through aqueous electrolyte solution. Most common reference electrode is 
Ag/AgCl electrodes while platinum, gold and carbon are examples of common counter 
electrodes. Electrochemical sensors hold a promising approach for developing POC 
sensors due to its high sensitivity, ease of automation, low cost and relatively simple 
instrumentation.  
Ability to immobilize antibodies on electrode with high surface coverage is a critical 
step in developing electrochemical biosensors. Working electrodes have been fabricated 
from a spectrum of materials including metals like gold and silver, carbon based materials 
like pyrolytic graphite and screen printed carbon, or nanoparticles like gold, silver and 
platinum nanoparticles.73 depending on the nature of the working electrode, antibodies are 




attached to surface through passive adsorption. Antibodies immobilized onto working 
electrodes serves as capture agents that selectively separate target analyte proteins from 
different matrices.  
Most electrochemical sensors adapt sandwich immunoassay protocol for separation 
and quantitation of target analytes. Each enzyme label will produce high number of soluble 
electroactive species in less than a second that result in a large electrochemical signal. But 
sandwich immunoassay protocol in electrochemical systems usually places the enzyme 
away from the electrode surface which require the use of mediator to shuttle electrons form 
electrode surface to enzyme. Mediators are usually an electroactive species that can 
undergo redox reaction on the electrode surface. Commonly used mediators include 
quinones, phenolic compounds and ferrocenes ex. Hydroquinone, anthraquinone, 
dopamine and ferrocene methanol.76,77 Alternatively, systems modified with carbon based 
carriers78,79 or nucleic acid80 have been introduced to eliminate the need of mediator and 
shuttle electrons directly to enzyme molecules (Fig. 1.3).   
Fig. 1.  3 strategies of electron transfer from electrode surface to labelling enzyme. (A) Use of 
mediator hydroquinone (HQ) to shuttle electrons from electrode surface to HRP and get 
oxidized to benzoquinone (BQ). (B) Use of single wall carbon nanotubes as an electron carrier 
that eliminate the need for mediators. (C) Labelling detection antibodies with DNA carrying 




         
Integration of electrochemical sensor in microfluidic devices have been an accessible 
strategy to develop POC diagnostics that can be used to quantify multiple proteins 
simultaneously (multiplexing). This is due to the ease of design and integration of multiple 
electrodes in a single microfluidic channel and availability of instrumentation to measure 
up to 32 electrochemical signals simultaneously.81,82    
B. Chemiluminescence microfluidic systems 
Similar to electrochemical microfluidic systems, chemiluminescence systems utilized 
sandwich immunoassay protocol format to label target antigens with enzyme. Signals are 
generated by a chemical reaction that yields an intermediate excited state that undergo 
radiative relaxation to ground state. Several approaches to improve the chemiluminescence 
sensor sensitivity have been studied including the use of photomultiplier tube to capture 
light, improve the substrate quantum yield, development of quantum dots, and recently use 
of multi-labeled enzyme systems.83,84,85 chemiluminescence sensors promise very high 
sensitivity, ability to capture signals using CCD or smartphone camera and ability to 
generate signal without the need for sophisticated electronic connections.86 HRP and ALP 
are the most common enzymes utilized in chemiluminescence microfluidic sensors. 
Luminol and its enhanced derivatives are most frequently and most efficient 
chemiluminescence substrates for the development of light in microfluidic systems. 
Luminol has been linked to ligands through its amine group with the loss of its quantum 
yield while its derivatives like iso-luminol did not suffer from such drawback. Luminol 
reacts with hydrogen peroxide in presence of HRP to form a stable excited intermediate 



















Several POC microfluidic chemiluminescence sensors have been developed to quantify 
proteins,87 DNA,88 RNA89 and even small molecules.90 Emitted light can be captured in 
dark on an x-ray film or using CCD camera which reduce the background noise associated 
with colorimetric and electrochemical techniques. Recently, capturing and quantifying 
luminescence is becoming more affordable due rapid development in smartphone cameras 
which makes chemiluminescence sensors a more appealing choice or POC diagnostics.    
 
 
Fig. 1.  4 Mechanism of the light generation from reaction of Luminol with hydrogen 
peroxide in presence of HRP. Luminol is exited to triplet dianion state in presence of HRP 
and hydrogen peroxide which undergo radiative relaxation to ground state by emitting 




C. Electrochemiluminescence microfluidic systems 
Electrochemiluminescent labels generate light when they are stimulated by electricity 
in appropriate chemical environment. Due to the confined nature of luminescence near the 
electrode surface, electrochemiluminescence sensors are excellent tool to multiplex 
analytes. Electrochemiluminescence assay usually provide a wider dynamic range for assay 
compared to other techniques while maintain excellent sensitivity. 91,92,93 
In electrochemiluminescence systems a lumiphore and its co-reactant are oxidized near 
the electrode surface, then react to produce luminescence (Fig. 1. 5).94 Many organic 
molecules have shown promising electrochemiluminescence characteristics. Tris(2,2′-
bipyridine)ruthenium(II) (Ru(bpy)3
2+) is one of the most studied 
electrochemiluminescence molecules due to its low molecular weight and ease to produce 
multi-labelled antibodies. The major advantage of ECL over fluorescence is the ability to 
excite the luminophore without the need for excitation light which in turn greatly reduces 
background noise. Backed with these advantages ECL has been utilized commercially in 
POC diagnostics like Mesoscale Discovery® and Roche® POC systems. Commercial ECL 
systems for detection of clinically relevant target analytes like proteins, hormones, steroids, 







1.9 Summary and Overview of dissertation  
Early detection and staging of cancer is a crucial step in more efficient cancer control and 
treatment. Despite advances in conventional diagnostic techniques like mammography and 
computed topography (CT), still early cancer diagnosis is a challenge. Recent developments in 
proteomics and immunology suggested that using protein biomarkers as a cancer detection tool 
may offer fast, reliable, non-invasive and cost-effective approach for early diagnosis. In this thesis 
we would like to investigate several microfluidic approaches for improved cancer diagnostics with 
better sensitivities and improved stability. In order to achieve a POC testing requirement we also 
studied the utilization of desktop 3D printers to prototype and fabricate accessible diagnostic tools.  
Fig. 1.  5 Mechanism of electrochemiluminescence generation in aqueous solution. Luminophore 
and its co-reactant are oxidized at the electrode surface. The co-reactant forms a radical that reduce 
the oxidized luminophore. Excited molecules return to original state by emitting light. Reproduced 




In this chapter, Chapter 1, we provided a description of the status quo of cancer and its current 
diagnostic tools. The major characteristics of POC diagnostic system have been discussed while 
highlighting the significance of using microfluidics to develop and improve cancer screening 
assays. The chapter also provided an insight into enzyme amplification as strategy to increase 
assay sensitivity and achieve low LOD. Finally, a detailed description of microfluidic fabrication 
techniques and signal transduction in microfluidic systems have been explained with detailed 
explanation of advantages provided by each technique.  
Chapter 2 describes Fe3O4@GO composite as a signal-transducing label in a sandwich 
immunoassay to detect prostate cancer biomarkers on screen-printed carbon electrode arrays 
housed in simple microfluidic devices. Antibodies for Prostate Specific Antigen (PSA) and 
Prostate Specific Membrane antigen (PSMA) were covalently attached to Fe3O4@GO, and the 
resulting bio-composite was used to isolate target antigens from serum and serve as a signal-
transducing label for electrochemical detection. The sensor surfaces of the array were coated with 
electrochemically reduced graphene oxide to improve conductivity and increase surface area, and 
capture antibodies were attached through either adsorption or covalent binding to residual 
carboxylic groups on surface.  An optimized simple microfluidic system was used to deliver 
reagents to the electrode arrays and wash/remove unbound species. This sandwich assay based on 
catalytic reduction of hydrogen peroxide by Fe3O4@GO exhibited detection limits of 15 fg/mL for 
PSA and 4.8 fg /mL for PSMA. Accuracy was validated by measuring PSA and PSMA in patient 
samples and results showed good correlation to values obtained from standard ELISA. 
 Chapter 3 introduced a low-cost pipette tip-based ELISA platform “ELISA in a Tip” as a next 
generation assay tool with better sensitivity, shorter incubation time, low sample and reagent 




encourages to blend microfluidic advancement, multiplexing and smartphone integration with 
widely practiced gold standard ELISA without need for major overhaul of current infrastructure 
in hospitals and testing laboratories. We applied this approach in detection of four cancer protein 
biomarkers, a prostate cancer panel with detection limits in low picogram range and a wider 
dynamic range compared to plate-based ELISA. Recoveries from spiked human serum samples 
were from 80% to 120% with standard deviation less than 15 %. We demonstrated the ability to 
utilize smartphone-based detection in our colorimetric detection approach that could be an ideal 
candidate for offering telemedicine to remote areas where quantitation assays for diseases like 
cancer are challenged. Using these techniques, we showed simultaneous detection of 4 biomarkers 
PSA, VEGF, IGFBP3 and CD-14 on an 8-channel pipette tip array with detection limits ranging 
from 1 pg mL-1 to 25 pg mL-1. We validated our method by calculating % recoveries from spiked 
human serum and observed acceptable recoveries ±20%. We were able to utilize colorimetry and 
chemiluminescence as a detectable signal output that can be measured using smartphone without 
compromising assay sensitivity.         
Chapter 4 explain development of 3D printed multifunctional array capable of onsite 
differentiation between metastatic and nonmetastatic head and neck squamous cell carcinoma 
(HNSCC). This chip first lyses cells in a novel microfluidic lysis chamber utilizing combination 
of mechanical and chemical lysis. Once cells are lysed, desmoglein3 (DSG3), vascular endothelial 
growth factor-C (VEGF-C) and beta tubulin (β-Tub) will be quantified in an 8 chambers detection 
compartment. Reagents and samples were delivered automatically to detection compartment using 
programmable micro pumps controlled by Arduino® microcontroller. Use of streptavidin 
poly(HRP) as a label with enhanced (West femto®) luminol substrate allowed sub femtogram 




normalize the chemiluminescence signal. Chemiluminescence signals were captured using CCD 
camera for 15s and quantified using GeneSnap® software. Assay time was less than 45 min and 
promised detection of biomarkers at single cell expression level.  
Chapter 5 provided a comprehensive study of antibody immobilization strategies on screen 
printed carbon electrodes. This is a crucial step in developing biosensor arrays as it would affect 
assay sensitivity, sensor stability and detection limits. The performance of immunosensors 
prepared using six different antibody immobilization techniques on screen-printed carbon 
electrodes was compared. anti-HRP was utilized as a model immunoglobulin (IgG) antibody to 
determine HRP in calf serum by performing amperometry in the presence of H2O2 and HQ. Results 
presented shed insights regarding the influence of the immobilization protocol on the coverage of 
antibodies and fraction of active ones immobilized, LOD, dynamic range, reproducibility and 
storage stability. Against previous findings, results demonstrated that while antibody orientation 
did not have a significant effect on LOD, it did enhance the dynamic range of the immunoassay.  
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Fe3O4 Nanoparticles on Graphene Oxide Sheets for Isolation and 




Ultrasensitive mediator-free electrochemical detection for biomarker proteins was achieved at 
low cost using a novel composite of Fe3O4 nanoparticles loaded onto graphene oxide (GO) nano-
sheets (Fe3O4@GO). This paramagnetic Fe3O4@GO composite (1 µm size range) was decorated 
with antibodies against prostate specific antigen (PSA) and prostate specific membrane antigen 
(PSMA), and then used to first capture these biomarkers and then deliver them to an 8-sensor 
detection chamber of a microfluidic immunoarray. Screen-printed carbon sensors coated with 
electrochemically reduced graphene oxide (ERGO) and a second set of antibodies selectively 
capture the biomarker-laden Fe3O4@GO particles, which subsequently catalyze hydrogen 
peroxide reduction to detect PSA and PSMA. Accuracy was confirmed by good correlation 
between patient serum assays and enzyme-linked immuno-sorbent assays (ELISA). Excellent 
detection limits (LOD) of 15 fg/mL for PSA and 4.8 fg/mL for PSMA were achieved in serum. 
The LOD for PSA was 1000-fold better than the only previous report of PSA detection using 
Fe3O4. Dynamic ranges were easily tunable for concentration ranges encountered in serum samples 






2.2 Introduction    
Accurate, sensitive, cost-effective measurements of multiple proteins in patient samples are critical 
for progress in clinical detection and monitoring of cancer.1,2 Recent advances in nanomaterials-
assisted assays by ourselves 3 and others 4,5,6,7,8 have improved multiplexed protein sensitivity up 
to 1000-fold compared to earlier established commercial assays. However, cost and assay 
complexity still raise barriers to translation of effective protein-based cancer diagnostics into 
widespread clinical and point-of-care (POC) use.9 
Enzyme-linked immunosorbent assays [ELISA] have long been the gold standard for clinical 
protein determinations, and typically achieve detection limits of 1-10 pg/mL for serum proteins.10 
ELISA employs enzyme labels attached to detection antibodies that have been pre-captured on an 
antibody-decorated well plate to measure proteins using optical detection of a colored enzyme 
reaction product. Many variations on this “sandwich assay” format, often utilizing magnetic beads, 
have been used in more modern, multiplexed commercial protein detection kits.3,11,12 In our recent 
work, magnetic beads loaded with massive numbers of horseradish peroxidase (HRP) labels and 
detection antibodies were used to achieve ultrasensitive multiplexed protein detection at levels as 
low as 5 fg/mL.13,14  
Iron oxide (Fe3O4) nanoparticles have peroxidase-like activity for catalysis of hydrogen 
peroxide (H2O2) reduction, which can be optically monitored by following the H2O2–assisted 
oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) or o-phenylendiamine (OPD).15,16,17,18  
Peroxidase-like activity of Fe3O4 nanoparticles for electrochemical detection of hydrogen peroxide 
has been enhanced by incorporation with other materials like platinum,19 graphene 
derivatives,20,21,22 platinum/palladium,23 and gold.24 Chitosan coated Fe3O4 nanoparticles were 




thrombin with LOD of 1 nM.26 Dumbbell-like gold-Fe3O4 was used for electrochemical detection 
of prostate specific antigen (PSA) with 5 pg/mL LOD and dynamic range of 0.01-10 ng/mL.27  
    Loading Fe3O4 nanoparticles onto graphene oxide (GO) nanosheets improved wettability 
and dispersion of the composite material.28,29 Fe3O4 loaded on GO was previously synthesized and 
utilized for removal of cobalt,30 hydrocarbons31 and organic dyes32 from environmental samples. 
Electrostatic interactions between negatively charged graphene oxide sheets and Fe3O4 
nanoparticles coated with positively charged poly(diallydimethylammonium chloride) (PDDA) 
were used to assemble core-shell Fe3O4@GO particles.33  
In this paper, we describe the first preparation and use of multiple-Fe3O4 nanoparticles 
assembled onto graphene oxide nanosheets and decorated with antibodies (Ab2) to first isolate 
biomarker proteins from the sample under magnetic control, and then electrochemically detect 
them at ultra-high sensitivity using the intrinsic peroxidase activity. Electrostatic interactions 
between intact GO sheets and PDDA-coated Fe3O4 nanoparticles (NP) provide precise control over 
the number of Fe3O4 NPs per GO sheet, and can be used to optimize the dynamic range of the 
assay. Here, Ab2-Fe3O4@GO particles were evaluated as substitutes for HRP-Ab2-magnetic beads 
(MB) (1 m diam.) in an 8-sensor microfluidic system featuring off-line capture of PSA and 
prostate specific membrane antigen (PSMA) on magnetic particles, followed by delivery of these 
analyte protein-laden particles to an amperometric detection chamber featuring 8-sensors 
decorated with capture antibodies (Ab1). Using this approach, we achieved ultrasensitive detection 
of PSA and SMA simultaneously with tunable dynamic range at low cost compared to HRP-





2.3 Materials and Methods  
2.3.1 Synthesis of Fe3O4@GO  
Fe3O4 nanoparticles were synthesized by a solvo-thermal method,
34 Graphene Oxide (GO) was 
prepared using a modified Hummer’s method.35,36 Briefly, 50 mg of Fe3O4 nanoparticles were 
sonicated 5 min with 10 mL 0.1 mg/mL poly(diallydimethylammonium chloride) (PDDA) in 
water, magnetically separated, washed 3x with water, and re-suspended in 25 mL water. GO (50 
mg) was sonicated in 25 mL water for 30 min after which the dispersion of PDDA-coated Fe3O4 
nanoparticles was added dropwise with stirring 1 hr.33 Fe3O4@GO composites were then 
magnetically separated, washed 3x with water, and dried overnight at 55 ̊C under vacuum. The 
Fe3O4@GO composite was suspended in water at the concentration required for each assay.  
ELISA kits used were Sigma Aldrich RAB0331 for PS and Lifeome Biolabs/Cusabio 
EL008782HU-96 for PSMA.  
2.3.2. Electrode preparation  
Electrochemically reduced graphene oxide (ERGO) was electrophoretically-deposited on the 
surface of 8-sensor screen-printed carbon arrays (Kanichi Research) from a dispersion of GO  (4 
mg/mL) in 0.1 M LiClO4 at -1.2 V for 60 s, then further reduced in 0.5 M LiClO4 for 60 s to 
increase conductivity and surface area. The ERGO-coated sensors were then washed 5X with water 
and dried under nitrogen.37 Antibodies were attached to these sensors through both adsorption and 
amidization after treating with 1-(3-(Dimethylamino)propyl)-3-ethylcarbodiimide hydrochloride 
(EDC)/N-hydroxysulfosuccinimide (NHSS) to activate ERGO carboxylate groups, then washing 
with water and incubating overnight with capture antibodies (Ab1) at 4 ̊C. Arrays were then washed 
with phosphate buffer (PBS) (pH 7.4) with 0.05% Tween 20 (PBS-T20) and incubated 1 hr with 




They were then washed again with PBS-T20 and inserted into the detection chamber of a 
microfluidic immunoarray that was previously described38 (Fig. 2.1) for protein detection. The 
detection chamber consists of a PDMS channel between two PMMA plates equipped with 
symmetrically placed reference Ag/AgCl electrode and counter Pt electrode. The chamber has an 
outlet and inlet connected to an injector and a syringe pump (Fig. 2.1). 
 
Fig. 2.1 Illustration of microfluidic immunoarray with an injector used to deliver captured protein 
on Ab2@Fe3O4@GO into a detection chamber equipped with Ag/AgCl reference electrode, Pt 
counter electrode and housing an 8 electrode ERGO-coated  sensor array (Kanichi®) connected  to 
8 an channel multi-potentiostat (see Malhotra, R. et al., 2012.) 
2.3.3. Off-line analyte protein capture  
The Fe3O4@GO composite was reacted with EDC/NHSS by stirring for 10 min to activate 
carboxylic groups on the GO, then reacted with antibodies (Ab2) by incubation overnight at 4 ̊C to 




washed 2x with 0.1% BSA, then incubated for 1 hr with 0.1 % BSA to minimize nonspecific 
binding. Protein biomarkers (antigen, Ag) were captured from samples by mixing with 
Ab2@Fe3O4@GO conjugates while stirring for 30 min.
38  Ab2@Fe3O4@GO with captured analyte 
proteins were then magnetically separated, washed with 0.1% BSA and dispersed in 120 µL 0.1% 
BSA. These Ab2@Fe3O4@GO-protein conjugates were delivered to the detection chamber 
through an injector equipped with a 100 µL sample loop. Once the particles filled the reaction 
chamber as monitored by the black color of the conjugates, the flow was stopped and the array 
was incubated for 30 min. to enable Ab2@Fe3O4@GO-protein capture on the Ab1-decorated 
sensors. Then, sensors were washed with PBS-T20 for 4 min at 100 µL/min to remove unbound 
species (Scheme 2.1).  
2.3.4. Protein Measurements   
Amperometric signals were generated by injecting 100 µL of 5 mM H2O2 in PBS at a flow rate 
of 100 µL/min and applying -0.3 V vs. Ag/AgCl (0.14 M NaCl). Amounts of Fe3O4@GO on the 
sensors depend on concentrations of captured biomarker proteins. To mimic human serum, 






Scheme 2.1 Protein capture and detection mediated by Fe3O4@GO sheets. Proteins captured by 
Fe3O4@GO decorated with detection antibodies. Composite with biomarker was then captured on 
the sensor surfaces coated with graphene and capture antibodies. Amperometric signal was 
generated by injecting 100 µL 5 mM H2O2 
 
2.4. Results and Discussion  
2.4.1. Characterization of Fe3O4@GO  
Dynamic light scattering (DLS) and scanning electron microscopy (SEM) images of Fe3O4 
nanoparticles revealed average diameters of 300 (±15) nm (Fig. 2.2 A,B). Zeta potential 




charge changed to +65 (±6) mV after coating Fe3O4 nanoparticles with polycationic PDDA. GO 
sheets exhibited an average size of 900 (±40) nm and surface charge of -79 ±7 mV. The negative 
surface charge of GO is due to oxygen-containing surface groups, e.g. carboxylate, epoxy, and 
hydroxyl.39 
When positively charged PDDA-coated Fe3O4 nanoparticles were mixed with negatively 
charged GO sheets, a composite of Fe3O4 nanoparticles bound to the surface of GO sheets 
(Fe3O4@GO) formed through electrostatic interactions with a final surface charge of -42 (±3). The 
Fe3O4@GO composite was readily dispersed in aqueous solution and then separated in 30 s using 
a magnet to isolate the particles (Fig. 2.2 E). The Fe3O4@GO composites had irregular shapes with 
an average size dimension of ~1.0 µm as seen in SEM images (Fig. 2.2 C,D,F). 
Peroxidase-like activity of Fe3O4@GO for hydrogen peroxide reduction was demonstrated by 
measuring the rate of oxidation of 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) 
diammonium salt (ABTS).40  In this standard assay the change in absorbance at 592 nm 
corresponds to the catalytic oxidation of ABTS in the presence of H2O2 to a colored product. 
Measured catalytic activity was 260 units per mg Fe3O4@GO, equivalent to catalytic activity of 






Fig. 2.2 Morphology of Fe3O4 nanoparticles: (A) SEM image showing two Fe3O4 nanoparticles 
and (B) DLS of Fe3O4 nanoparticles with average diameter 300 nm. (C & D) SEM Images of Fe3O4 
on surface of GO sheets showing morphology of Fe3O4@GO, (E) Magnetic attraction of 
Fe3O4@GO nanoparticles in the cuvette to the magnet on the right (F) DLS of Fe3O4@GO 
composite 
 
For voltammetry, the negatively charged Fe3O4@GO composites, (0.1 mg/mL) were attached 
to screen-printed carbon electrodes in the array through alternating electrostatic layer-by-layer 
(LBL) assembly using aqueous 2 mg/mL PDDA solution as the alternate-layer polycation. After 
washing, cyclic and square wave voltammograms (CV, SWV) of PDDA/Fe3O4@GO electrodes in 
0.1 M PBS buffer showed a large increase in peak current when the concentration of H2O2 was 
increased compared to a bare electrode (Fig. 2.3). Catalytic peak current of the Fe3O4@GO 




currents (Fig. 2.3). These results confirmed the high catalytic activity of Fe3O4@GO for the 
reduction of H2O2, and the ability of this material to serve as a label in electrochemical detection. 
Fig.2.3 Catalytic reduction of H2O2 by Fe3O4@GO on Kanichi® screen printed carbon array 
electrodes: (A) CV of Fe3O4@GO coated electrode in absence and presence of increasing 
concentrations (2-50 mM) of H2O2 in 0.1 M phosphate buffer (pH 7.4) against Ag/AgCl (0.14M 
NaCl) at 100 mV/s, (B) square wave voltammograms (SWV) at 5 Hz of Fe3O4@GO coated 
electrode in absence and presence of increasing concentrations (2-50 mM) of H2O2 in 0.1 M 
phosphate buffer (pH 7.4), and (C) plots of peak current of SWV against increasing concentration 






A bicinchoninic acid (BCA) total protein assay was used estimate the amount of antibodies 
loaded on Fe3O4@GO (Noble and Bailey, 2009).
41 Loading capacity was found to be 1.52 µg of 
proteins per 1 mg Fe3O4@GO which represents around 2.25x10
12 antibodies /mg Fe3O4@GO (Fig 
2.4).  
Fig. 2.4 Standard Calibration curve for measurement of series of concentrations of standard PSA 
detection antibody (Ab2) using BCA protein detection kit at 545 nm.  
 
Electrical conductivity of the Fe3O4@GO as well as GO and Fe3O4 films were measured using 
the standard four-probe method.42 Conductivities were 52 (±11) S/cm for GO, 4.0X10-3 (±7.0X10-




2.4.2. Sensor Characterization 
Array sensor surface areas before and after coating with ERGO were estimated by CV using 
the Randles-Sevcik equation43 with 1 mM ruthenium hexamine chloride as a redox probe in 0.1 M 
KCl. Surface area of the screen-printed carbon electrode was 9.7±0.1 x10
-4 cm2 and increased to 
2.0±0.1 x10-3 cm2 after depositing ERGO (Fig. 2.5).  
Fig. 2.5 Cyclic voltammetry characterization of bare and ERGO coated sensor array using 0.5 mM 
Fc-MeOH in 0.1 M TEAP vs Ag/AgCl (0.14M NaCl) showing (A) Plot of peak current vs. square 
root of the scan rate for the bare electrode, (B) Cyclic voltammograms at different scan rates (from 
10 to 200 mV/s) for bare electrode, (C) Peak current plot for ERGO coated electrode, (D) Cyclic 





The increase in electrochemical active surface area is due to the increased roughness of the 
surface after deposition of ERGO (Fig. 2.6).   
Fig. 2.6 Morphology of the Kanichi® carbon electrodes: (A), (B) SEM images of bare electrode, 
(C), (D) SEM images of electrode after first reduction cycle in 4 mg/mL GO/0.1 M LiClO4 at -
1.2V vs Ag/AgCl (0.14 M NaCl) reference electrode, and (E),(F) SEM images of electrode after 
second reduction cycle in 4 mg/mL GO/0.5 M LiClO4 at -1.2V vs. Ag/AgCl (0.14 M NaCl) 






2.4.3. Optimization  
Analytes chosen to demonstrate system performance (PSA and PMSA) in serum are 
overexpressed in prostate cancers. PSA is an intercellular glycoprotein (34 kDa kallikrein-like 
protease) that is locally synthesized in prostatic tissue.44 PSA levels higher than 4 ng/mL or rising 
levels with time are indicatives of prostate cancer.45 PSMA is a cell-surface glycoprotein with 
average plasma levels in males above 50 at 360 ng/mL and 275 ng/mL in males younger than 50.46 
Plasma levels can increase above 600 ng/mL in prostate cancer patients.47  
The system in Figure 1 was optimized to measure the analyte proteins with specific capture 
antibodies attached onto the sensors. The analyte proteins were first captured by detection 
antibodies (Ab2) immobilized on Fe3O4@GO in a test tube and magnetically separated. Then the 
protein-Ab2-Fe3O4@GO bio-conjugate was delivered to the detection chamber (See 
Experimental). The protein-Ab2-Fe3O4@GO conjugates were captured by Ab1 on sensor surfaces 
under stopped flow, and unbound conjugates were then washed away. Amounts of Fe3O4@GO 
bound to the sensor were proportional to the specific protein concentrations, as was the 
amperometric peak current due to the decomposition of H2O2 catalyzed by Fe3O4 nanoparticles in 
the detection step. 
Concentrations of Ab1 on sensors and Ab2 on Fe3O4@GO were optimized first in order to 
achieve the largest signal to noise ratio for PSA and PSMA proteins in undiluted calf serum. To 
optimize Ab1, other experimental parameters including Ab2 concentration were kept constant while 
varying Ab1 concentration. Similar procedures were used to optimize Ab2 concentration while 
keeping Ab1 constant.  Optimal Ab1 concentrations in the sensor reaction mixture were 100 µg/mL 
for both PSA and PSMA, while the optimal Ab2 concentration was 20 µg/mL for PSA and 25 




Fig. 2.7 Optimization of capture antibodies (Ab1) Concentrations on the sensor array for (A) PSA 
and (C) PSMA. Optimization of detection antibodies (Ab2) concentrations loaded om magnetic 
beads for (B) PSA and (D) PSMA. Signals were generated by injecting 5 mM H2O2 in 0.1 M PBS 
buffer at –0.3 V against Ag/AgCl (0.14 M NaCl)  
 
2.4.4. Detection of PSA and PSMA   
Optimized Ab1 and Ab2 concentrations were used to detect single biomarker proteins utilizing 
different concentrations of the Fe3O4@GO to tune the dynamic range and limits of detection (LOD, 
as 3X SD above blank) of the assay. For the most sensitive PSA assay, we used a high 




nA/(log(pg/mL)sensitivity, LOD 15 fg/mL and dynamic range of 61 fg/mL to 3.9 pg/mL. To 
achieve a higher concentration dynamic range, we used a lower concentration of Fe3O4@GO 
(0.5mg/mL) to get 105 nA/(log(pg/mL) sensitivity with a LOD 4.9 pg/mL and dynamic range of 
9.8 pg/mL to 624 pg/mL (Fig.2.8).                                                                                                                
Fig. 2.8 Results from n=8. microfluidic array for standard solutions of PSA in calf serum (A) peak 
currents using 2 mg/mL Fe3O4@GO and (B) calibration plot (control subtracted) using 2 mg/mL 
Fe3O4@GO, n=8 (C) peak currents using 0.5 mg/mL Fe3O4@GO and (D) calibration plot (control 
subtracted) using 0.5 mg/mL Fe3O4@GO , n=8. Signals at -0.3 V vs Ag/AgCl (0.14 M NaCl) after 






For PSMA, using a 2 mg/mL concentration of Fe3O4@GO, LOD was 4.8 fg/mL with 0.0611 
nA/(log(pg/mL) sensitivity and dynamic range was 9.8 fg/mL to 10 pg/mL. With 0.5 mg/mL 
Fe3O4@GO, and LOD 15.6 pg/mL , the dynamic range was 15.6 pg/mL to 7.8 ng/mL with 25.9 
nA/(log(pg/mL) sensitivity (Fig. 2.9).  
Fig. 2.9 Amperometric responses in the microfluidic immunoarray for (A) standard PMSA in 
undiluted calf serum and (B) calibration plot using 2 mg/mL Fe3O4@GO, control subtracted, n=8 
(C) Amperometric responses for individual standard solutions of PMSA in undiluted calf serum 
and (D) calibration plot using 0.5 mg/mL Fe3O4@GO, control subtracted, n=8. Signals developed 
by injecting 100 μL 5 mM H2O2 detected at -0.3 V vs Ag/AgCl (0.14 M NaCl).  
Serum levels for PSA in prostate cancer patients is >4 ng/mL and that for PSMA is >300 
ng/mL.45,47 Concentrations of Fe3O4@GO were tuned for multiplexing both biomarkers on the 




conjugates, 0.5 mg/mL Fe3O4@GO was used to label PSMA Ab2 while 1.0 mg/mL Fe3O4@GO 
was used to label PSA Ab2. Using this protocol, the PSA was tuned to LOD 1.25 pg/mL with a 
dynamic range of 1.25 to 1000 pg/mL while PSMA was tuned to LOD 9.7 pg/mL with a dynamic 
range of 9.7 to 5000 pg/mL (Fig. 2.10). This approach allowed dilution of patient serum by 100-
fold in buffer to bring concentrations into dynamic ranges. 
 
 
Fig. 2.10 Amperometric responses from microfluidic immunoarray in mixtures: (A) PSA and (C) 
PSMA. Along with multiplexed calibrations of: (B) PSA and (D) PSMA in calf serum using 1 






2.4.5. Assay validation   
PSA and PSMA were determined in 3 pooled prostate cancer patient serum samples and one 
negative control human sample (Capital Bioscience Inc.) and compared to single protein ELISA 
assays. 10 µL of each sample was diluted 100x in PBS. Samples were also spiked with varying 
concentrations (100-500 ng/mL) of PSMA as an additional accuracy test, since initial analyses 
showed very low concentrations of this protein (less than 20 ng/mL). Immunoarray results showed 
very good correlation with the results obtained from single protein ELISA (Fig. 2.11). Linear 
correlation plots of the immunoassay against ELISA showed slopes near unity, 1.118±0.042 for 
PSA and 1.025±0.019 for PSMA, and intercepts close to zero, -0.611±0.319 for PSA and 2.0±6.6 





Fig. 2.11 Multiplexed immunoarray compared to single-protein ELISA results for patient samples 
for (A) PSA and (B) PSMA and linear correlation plots of immunoarray against ELISA for (C) 
PSA and (D) PSMA  
 
The above results demonstrated the use of Fe3O4 nanoparticles on graphene oxide sheets (Fig. 2.2) 
decorated with antibodies to facilitate both analyte protein capture and electrochemical detection 
(Scheme 2.1) in a simple microfluidic device for sensitive measurements of proteins. Prostate 
cancer biomarker proteins PSA and PSMA were detected in diluted serum with LODs in the low 




GO sheet provides a huge amplification of the amperometric signal per protein. The GO sheets 
also allow attachment of a large number of detection antibodies leading very efficient protein 
capture, analogous to other multi-antibody particles.48 In addition to previous advantages of using 
GO sheets, we believe micrometer-sized GO sheets facilitated the transfer of electrons from 
electrode surface to nanoparticles which further improve their catalytic properties. This approach 
provided sensitivity roughly equivalent to that obtained using 1 µm diam. magnetic beads coated 
with massive numbers of Ab2 and HRP labels.
13,38 This LOD is 1000-fold better than the only 
previous report of using Fe3O4 (as gold-Fe3O4) as an electrochemical label for detection of PSA.
27 
  Excellent reproducibility was obtained as evidenced by the small error bars in multiple 
measurements (Figures 2.8, 2.9 and 2.10). The Fe3O4@GO conjugates provide a low-cost material 
stabilized by virtue of multiple co-operative binding events on the GO sheets. In addition to 
catalytic activity of Fe3O4 nanoparticles providing the detection approach, they also provide 
magnetic control that facilitates separation and washing. Electrodes decorated with capture 
antibodies were stable for 3 days at 4 ̊C after which 20% of the activity were lost on day 4 (Fig. 










Fig. 2.12 Amperometric responses in the microfluidic immunoarray for (A) standard 20 pg/mL 
PSA in undiluted calf serum in 4 successive days, (B) standard 7ng /mL PSMA in undiluted calf 
serum in 4 successive days 
 
Sensitivities as given by the slopes of the calibration curves (Fig. 2.8 and Fig. 2.9) and LODs 
in calf serum can be easily tuned in this system by adjusting the amounts of Fe3O4@GO composite 
used in the assay. For PSA, sensitivity can be tuned from 0.036 nA/log (pg/mL) to 10.5 nA/log 
(pg/mL) and from 0.061 nA/log (pg/mL) to 25.9 nA/log (pg/mL) for PSMA. In contrast, other 
assay done using the same offline protein capture technique in a similar microfluidic device 
utilizing magnetic beads labeled with 400,000 HRP had a sensitivity of 5.9 to 6.8 nA/log 
(pg/mL).38 LOD was 15 fg/mL for PSA and 4.8 fg/mL for PSMA which is comparable to those 
obtained in other multiplexed protein assays using commercial magnetic beads labeled with 
multiple HRPs and Ab2. 
13,14 Tuning of these enzyme-label assays can be done by changing the 
number of HRPs on the beads and/or by changing bead size, but both approaches require new 




reagents for 2-protein assays using Fe3O4@GO was $0.85, only 30% of the cost of the same assay 
with commercial magnetic beads and HRP which cost around $3.00 / 2-protein assays.14   
Multiplexing is important in protein-based cancer diagnostics to lower incidence false positives 
and false negatives encountered with less reliable single protein biomarker-based assays.3  
Multiplexed protein detection is easily optimized in the present assay system by tuning the 
dynamic range of the assay for each protein concentration level expected in the particular samples 
at hand by adjusting the amount of Fe3O4@GO used to prepare Ab2-Fe3O4@GO for each protein 
(Figure 4). Tuning the dynamic ranges allowed simultaneous detection of two protein biomarkers 
in the same assay here, in which the serum level of PSMA can be up to 80-fold larger than that of 
PSA (Fig. 2.11). 
Coating the screen-printed carbon sensor electrodes with electrochemically reduced GO 
facilitated immobilization of a large number of capture antibodies and also improves the 
conductivity of the electrode surface. While GO is a semiconductor with 52 (±11) S/cm 
conductivity, incorporation of Fe3O4 onto the surface did not impair semi-conductive character of 
the Fe3O4@GO composite that had a conductivity of 17 (±2) S/cm.
49  
The assay gave excellent accuracy as shown by the good correlation to single protein ELISA 
with slopes of unity and near zero intercepts (Fig. 2.11). Sample required was only 10 µL diluted 
100 times to fit into the dynamic range of the multiplexed assay that was enough for three or more 
runs. Ability to detect PSA and PSMA in human serum samples that contain hundreds of other 
proteins demonstrated the high selectivity of the assay.  
2.5. Conclusion  
An ultrasensitive, tunable mediator-free, enzyme-free immunoarray protocol using magnetic 
Fe3O4@GO composites was demonstrated for the detection of two prostate cancer biomarkers. 




detection. Ease of tunability allowed easy tailoring of protocols to simultaneously detect PSMA at 
levels up to 80-fold more concentrated than PSA in patient samples. Accuracy was demonstrated 
by excellent correlation of patient serum sample immunoarray results with ELISA. 
2.6. References 
1 Kulasingam, V.; Diamandis, E. P. Strategies for Discovering Novel Cancer Biomarkers through 
Utilization of Emerging Technologies. Nat. Clin. Pract. Oncol. 2008, 5 (10), 588–599. 
2 de Gramont, A.; Watson, S.; Ellis, L. M.; Rodón, J.; Tabernero, J.; de Gramont, A.; Hamilton, S. 
R. Pragmatic Issues in Biomarker Evaluation for Targeted Therapies in Cancer. Nat. Rev. Clin. 
Oncol. 2015, 12 (4), 197–212. 
3 Rusling, J. F.; Bishop, G. W.; Doan, N.; Papadimitrakopoulos, F. Nanomaterials and Biomaterials 
in Electrochemical Arrays for Protein Detection. J. Mater. Chem. B Mater. Biol. Med. 2014, 2 
(1). 
4 Zhang, Y.; Guo, Y.; Xianyu, Y.; Chen, W.; Zhao, Y.; Jiang, X. Nanomaterials for Ultrasensitive 
Protein Detection. Adv. Mater. Deerfield Beach Fla 2013, 25 (28), 3802–3819. 
5 Meissner, E. G.; Decalf, J.; Casrouge, A.; Masur, H.; Kottilil, S.; Albert, M. L.; Duffy, D. 
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in 
HCV Subjects Receiving Interferon-Free Therapy. PLOS ONE 2015, 10 (7), e0133236. 
6 Kelley, S. O.; Mirkin, C. A.; Walt, D. R.; Ismagilov, R. F.; Toner, M.; Sargent, E. H. Advancing 
the Speed, Sensitivity and Accuracy of Biomolecular Detection Using Multi-Length-Scale 
Engineering. Nat. Nanotechnol. 2014, 9 (12), 969–980. 
7 Das, J.; Kelley, S. O. Protein Detection Using Arrayed Microsensor Chips: Tuning Sensor 
Footprint to Achieve Ultrasensitive Readout of CA-125 in Serum and Whole Blood. Anal. 
Chem. 2011, 83 (4), 1167–1172. 
8 Lam, B.; Das, J.; Holmes, R. D.; Live, L.; Sage, A.; Sargent, E. H.; Kelley, S. O. Solution-Based 






9 Rusling, J. F. Multiplexed Electrochemical Protein Detection and Translation to Personalized 
Cancer Diagnostics. Anal. Chem. 2013, 85 (11), 5304–5310. 
10 Lequin, R. M. Enzyme Immunoassay (EIA)/Enzyme-Linked Immunosorbent Assay (ELISA). 
Clin. Chem. 2005, 51 (12), 2415–2418. 
11 Zhang, Y.; Guo, Y.; Xianyu, Y.; Chen, W.; Zhao, Y.; Jiang, X. Nanomaterials for Ultrasensitive 
Protein Detection. Adv. Mater. Deerfield Beach Fla 2013, 25 (28), 3802–3819. 
12 Dixit, C. K.; Kadimisetty, K.; Otieno, B. A.; Tang, C.; Malla, S.; Krause, C. E.; Rusling, J. F. 
Electrochemistry-Based Approaches to Low Cost, High Sensitivity, Automated, Multiplexed 
Protein Immunoassays for Cancer Diagnostics. The Analyst 2016, 141 (2), 536–547. 
13 Otieno, B. A.; Krause, C. E.; Latus, A.; Chikkaveeraiah, B. V.; Faria, R. C.; Rusling, J. F. On-
Line Protein Capture on Magnetic Beads for Ultrasensitive Microfluidic Immunoassays of 
Cancer Biomarkers. Biosens. Bioelectron. 2014, 53, 268–274. 
14 Krause, C. E.; Otieno, B. A.; Latus, A.; Faria, R. C.; Patel, V.; Gutkind, J. S.; Rusling, J. F. 
Rapid Microfluidic Immunoassays of Cancer Biomarker Proteins Using Disposable Inkjet-
Printed Gold Nanoparticle Arrays. ChemistryOpen 2013, 2 (4), 141–145. 
15 Zhang, L.; Zhai, Y.; Gao, N.; Wen, D.; Dong, S. Sensing H2O2 with Layer-by-Layer Assembled 
Fe3O4–PDDA Nanocomposite Film. Electrochem. Commun. 2008, 10 (10), 1524–1526. 
16 Chang, Q.; Deng, K.; Zhu, L.; Jiang, G.; Yu, C.; Tang, H. Determination of Hydrogen Peroxide 
with the Aid of Peroxidase-like Fe3O4 Magnetic Nanoparticles as the Catalyst. Microchim. 
Acta 2009, 165 (3–4), 299.   
17 Liu, Y.; Yuan, M.; Qiao, L.; Guo, R. An Efficient Colorimetric Biosensor for Glucose Based on 
Peroxidase-like Protein-Fe3O4 and Glucose Oxidase Nanocomposites. Biosens. Bioelectron. 
2014, 52, 391–396. 
18 Wei, H.; Wang, E. Fe3O4 Magnetic Nanoparticles as Peroxidase Mimetics and Their 





19 Ma, M.; Xie, J.; Zhang, Y.; Chen, Z.; Gu, N. Fe3O4@Pt Nanoparticles with Enhanced 
Peroxidase-like Catalytic Activity. Mater. Lett. 2013, 105, 36–39. 
20 Fang, H.; Pan, Y.; Shan, W.; Guo, M.; Nie, Z.; Huang, Y.; Yao, S. Enhanced Nonenzymatic 
Sensing of Hydrogen Peroxide Released from Living Cells Based on Fe3O4/Self-Reduced 
Graphene Nanocomposites. Anal. Methods 2014, 6 (15), 6073–6081. 
21 Liu, X.; Zhu, H.; Yang, X. An Amperometric Hydrogen Peroxide Chemical Sensor Based on 
Graphene-Fe3O4 Multilayer Films Modified ITO Electrode. Talanta 2011, 87, 243–248.  
22 Yang, X.; Wang, L.; Zhou, G.; Sui, N.; Gu, Y.; Wan, J. Electrochemical Detection of H2O2 
Based on Fe3O4 Nanoparticles with Graphene Oxide and Polyamidoamine Dendrimer. J. Clust. 
Sci. 2014, 26 (3), 789–798. 
23 Sun, X.; Guo, S.; Liu, Y.; Sun, S. Dumbbell-like PtPd–Fe3O4 Nanoparticles for Enhanced 
Electrochemical Detection of H2O2. Nano Lett. 2012, 12 (9), 4859–4863. 
24 Sun, H.; Jiao, X.; Han, Y.; Jiang, Z.; Chen, D. Synthesis of Fe3O4-Au Nanocomposites with 
Enhanced Peroxidase-Like Activity. Eur. J. Inorg. Chem. 2013, 2013 (1), 109–114. 
25 Gao, L.; Wu, J.; Lyle, S.; Zehr, K.; Cao, L.; Gao, D. Magnetite Nanoparticle-Linked 
Immunosorbent Assay. J. Phys. Chem. C 2008, 112 (44), 17357–17361. 
26 Zhang, Z.; Wang, Z.; Wang, X.; Yang, X. Magnetic Nanoparticle-Linked Colorimetric 
Aptasensor for the Detection of Thrombin. Sens. Actuators B Chem. 2010, 147 (2), 428–433. 
27 Wei, Q.; Xiang, Z.; He, J.; Wang, G.; Li, H.; Qian, Z.; Yang, M. Dumbbell-like Au-Fe3O4 
Nanoparticles as Label for the Preparation of Electrochemical Immunosensors. Biosens. 
Bioelectron. 2010, 26 (2), 627–631. 
28 Dong, Y.; Zhang, H.; Rahman, Z. U.; Su, L.; Chen, X.; Hu, J.; Chen, X. Graphene Oxide-Fe3O4 
Magnetic Nanocomposites with Peroxidase-like Activity for Colorimetric Detection of 





29 Wu, X.; Zhang, Y.; Han, T.; Wu, H.; Guo, S.; Zhang, J. Composite of Graphene Quantum Dots 
and Fe3O4 Nanoparticles: Peroxidase Activity and Application in Phenolic Compound 
Removal. RSC Adv. 2013, 4 (7), 3299–3305. 
30 Liu, M.; Chen, C.; Hu, J.; Wu, X.; Wang, X. Synthesis of Magnetite/Graphene Oxide Composite 
and Application for Cobalt(II) Removal. J. Phys. Chem. C 2011, 115 (51), 25234–25240. 
31 Han, Q.; Wang, Z.; Xia, J.; Chen, S.; Zhang, X.; Ding, M. Facile and Tunable Fabrication of 
Fe3O4/Graphene Oxide Nanocomposites and Their Application in the Magnetic Solid-Phase 
Extraction of Polycyclic Aromatic Hydrocarbons from Environmental Water Samples. Talanta 
2012, 101, 388–395. 
32 Jiao, T.; Liu, Y.; Wu, Y.; Zhang, Q.; Yan, X.; Gao, F.; Bauer, A. J. P.; Liu, J.; Zeng, T.; Li, B. 
Facile and Scalable Preparation of Graphene Oxide-Based Magnetic Hybrids for Fast and 
Highly Efficient Removal of Organic Dyes. Sci. Rep. 2015, 5, 12451. 
33 Wei, H.; Yang, W.; Xi, Q.; Chen, X. Preparation of Fe3O4@graphene Oxide Core–Shell 
Magnetic Particles for Use in Protein Adsorption. Mater. Lett. 2012, 82, 224–226. 
34 Deng, H.; Li, X.; Peng, Q.; Wang, X.; Chen, J.; Li, Y. Monodisperse Magnetic Single-Crystal 
Ferrite Microspheres. Angew. Chem. Int. Ed. 2005, 44 (18), 2782–2785. 
35 Kim, M. I.; Kim, M. S.; Woo, M.-A.; Ye, Y.; Kang, K. S.; Lee, J.; Park, H. G. Highly Efficient 
Colorimetric Detection of Target Cancer Cells Utilizing Superior Catalytic Activity of 
Graphene Oxide-Magnetic-Platinum Nanohybrids. Nanoscale 2014, 6 (3), 1529–1536. 
36 Hummers, W. S.; Offeman, R. E. Preparation of Graphitic Oxide. J. Am. Chem. Soc. 1958, 80 
(6), 1339–1339. 
37 Sheng, K.; Sun, Y.; Li, C.; Yuan, W.; Shi, G. Ultrahigh-Rate Supercapacitors Based on 
Eletrochemically Reduced Graphene Oxide for Ac Line-Filtering. Sci. Rep. 2012, 2.   
38 Malhotra, R.; Patel, V.; Chikkaveeraiah, B. V.; Munge, B. S.; Cheong, S. C.; Zain, R. B.; 





Biomarkers in the Clinic by Use of a Nanostructured Microfluidic Array. Anal. Chem. 2012, 84 
(14), 6249–6255. 
39 Loh, K. P.; Bao, Q.; Eda, G.; Chhowalla, M. Graphene Oxide as a Chemically Tunable Platform 
for Optical Applications. Nat. Chem. 2010, 2 (12), 1015–1024. 
40 Biochemica, B. M. G. Biochemica information: a revised biochemical reference source; 
Boehringer Mannheim GmbH, Biochemica, 1987. 
41 Noble, J. E.; Bailey, M. J. A. Quantitation of Protein. Methods Enzymol. 2009, 463, 73–95. 
42 Smits, F. M. Measurement of Sheet Resistivities with the Four-Point Probe. Bell Syst. Tech. J. 
1958, 37 (3), 711–718. 
43 Bard, A. J.; Faulkner, L. R. Electrochemical Methods: Fundamentals and Applications; Wiley, 
2000. 
44 Stamey, T. A.; Teplow, D. B.; Graves, H. C. B. Identity of PSA purified from seminal fluid by 
different methods: Comparison by amino acid analysis and assigned extinction coefficients. 
The Prostate 1995, 27 (4), 198–203. 
45 Smith, R. A.; Cokkinides, V.; Eyre, H. J. American Cancer Society Guidelines for the Early 
Detection of Cancer, 2005. CA. Cancer J. Clin. 2005, 55 (1), 31–44; quiz 55–56. 
46 O’Keefe, D. S.; Su, S. L.; Bacich, D. J.; Horiguchi, Y.; Luo, Y.; Powell, C. T.; Zandvliet, D.; 
Russell, P. J.; Molloy, P. L.; Nowak, N. J.; et al. Mapping, Genomic Organization and Promoter 
Analysis of the Human Prostate-Specific Membrane Antigen Gene. Biochim. Biophys. Acta 
1998, 1443 (1–2), 113–127. 
47 Xiao, Z.; Adam, B. L.; Cazares, L. H.; Clements, M. A.; Davis, J. W.; Schellhammer, P. F.; 
Dalmasso, E. A.; Wright, G. L. Quantitation of Serum Prostate-Specific Membrane Antigen by 
a Novel Protein Biochip Immunoassay Discriminates Benign from Malignant Prostate Disease. 





48 Mani, V.; Wasalathanthri, D. P.; Joshi, A. A.; Kumar, C. V.; Rusling, J. F. Highly Efficient 
Binding of Paramagnetic Beads Bioconjugated with 100,000 or More Antibodies to Protein-
Coated Surfaces. Anal. Chem. 2012, 84 (23), 10485–10491. 
49 Li, Z. J.; Yang, B. C.; Zhang, S. R.; Zhao, C. M. Graphene Oxide with Improved Electrical 





Accessible Telemedicine Diagnostics with ELISA in a 3D 
Printed Pipette Tip 
 
3.1 Abstract 
We report herein a novel pipette-based “ELISA in a Tip” as a new versatile diagnostic tool 
featuring better sensitivity, shorter incubation time, accessibility, and low sample and reagent 
volumes compared to traditional ELISA. Capture and analysis of data by a cell phone facilitates 
electronic delivery of results to health care providers. Pipette tips were designed and 3D printed as 
adapters to fit most commercial 50-200 µL pipettes. Capture antibodies (Ab1) are immobilized on 
inner walls of the pipette tip that serves as the assay compartment where samples and reagents are 
moved in and out by pipetting. Signals are generated using colorimetric or chemiluminescent (CL) 
reagents and can be quantified using a cell phone, CCD camera, or plate reader. We utilized 
pipette-tip ELISA to detect four cancer biomarkers proteins with detection limits similar to or 
lower than microplate ELISAs at 25% assay cost and time. Recoveries of these proteins from 
spiked human serum was 85-115% or better, depending slightly on detection mode. Using CCD 
camera quantification of CL with femto-luminol reagent gave limits of detection (LOD) as low as 
0.5 pg/mL. Patient samples (13) were assayed for 3 biomarker proteins with results well correlated 






3.2 Introduction  
Enzyme Linked Immunosorbent Assay (ELISA) has long been the gold standard for measuring 
proteins, pathogens, antibodies and other biomolecules in complex matrices.1,2,3 Recent research 
has focused on developing innovative and accessible systems in order to decrease cost and assay 
time, and increase sensitivity. Many ELISA systems use microplates with different volumes and 
sizes as assay compartments to immobilize antibodies that specifically capture target molecules 
followed by labor intensive, time-consuming incubation and washing steps. Recent approaches 
have included design of new labels to replace enzymes,4,5 utilizing magnetic beads,6,7 signal 
enhancement by nanomaterials,8 and developing more accessible plate readers.9,10 3D printing has 
been utilized to increase microwell surface area improved the performance of microplate ELISA.11 
Remaining challenges that hinder the use of ELISA for low cost diagnostics include limited surface 
area for antibody immobilization, fluid handling, multiplexing, and sample size.12  
Commercial alternatives for biomolecule detection include multiplexed microbead 
immunoassay technologies with optical or electrochemiluminescent (ECL) readout with LODs for 
proteins similar to standard ELISA at 1-10 pg mL-1.13,14,15 The Simoa HD-116 single protein 
counting device detects proteins with much better LODs, e.g. 4-70 fg mL-1.17 However, instrument 
and assay costs for these methods are high and prohibitive for many applications. 
Incorporation of microfluidics into molecular diagnostic devices facilitates fluid control, 
decreases sample and reagent volumes, decreases assay time and cost, and can enable remote 
sensing.18 Microfluidics has improved immunoassay performance by enhancing reaction kinetics, 
providing multiplexing and decreasing assay time and cost.19,20 ELISA has been integrated into 
PDMS chips,21,22 centrifugal assay platforms, 23,24 disposable patterned discs 25,26 and microfluidic 




there are as yet few off-the-shelf systems available, so for widespread lab use these approaches 
will require in-house fabrication that will not be familiar or desirable to many users.28,29    
3D printing provides fast, low cost, readily accessible fabrication of microfluidic devices.30,31,32 
Desktop 3D printing allows laboratories around the world to reproduce bioanalytical diagnostic 
microfluidic devices at low cost.33  3D printed microfluidic electrochemical immunoarrays have 
been developed for determining proteins, 34,35,36,37,38 nucleic acids,39,40,41 and small molecules.42,43 
Other detection modes are also possible and we have reported 3D printed microfluidic 
immunoarrays to detect up to 8 proteins utilizing electrochemiluminescence (ECL) or 
chemiluminescence (CL).44,45,46  
In the present paper, we report the first example of ELISA in 3D printed pipette tips. Our goal 
was to develop a simple, easy-to-use, low cost methodology for sandwich ELISA assays for 
virtually any protein. The tips were designed to fit to most commercially available 50-200 µL 
single and multichannel pipettes. The inner fluidic chamber of the tip serves as a solid support to 
strongly adsorb chitosan hydrogel, allowing covalent immobilization of capture antibodies (Ab1). 
The microfluidic nature of the assay chamber decreases assay time due to larger volume/surface 
area ratios than microwells. Sample and reagents are drawn into the tip and incubated there, and 
measurement of resulting absorbance or CL is done with a CCD camera, cell phone or plate reader. 
Four protein biomarkers, Prostate Specific Antigen (PSA), Vascular Endothelial Growth Factor 
(VEGF), Insulin like Growth Factor-1 (IGF-1) and Cluster of Differentiation-14 (CD-14), were 
detected simultaneously using tetramethylbenzidine (TMB) reagent and an 8-channel pipette tip 
adaptor. Limits of detection (LOD) were 5 pg/mL for PSA, 25 pg/mL for VEGF, 2.5 pg/mL for 
IGF-1 and 0.5 pg/mL for CD-14 which are lower than or similar to microplate ELISA in <25% of 




pg/mL and for IGF-1 with LOD 20 pg/mL. Integration with chemiluminescence (CL) detection 
was shown by measuring PSA using West Femto luminol with LOD 1 pg/mL. Recoveries from 
spiked human serum samples were between 85%-115%. In addition, proteins PSA, CD-14 and 
IGF-1 were quantified in 13 patient samples and data correlated well with both conventional 
ELISA and an established electrochemical immunoassay. Cell phone image capture was also used 
to quantify IGF-1 levels in 13 patient samples with good correlation to conventional ELISA.  
 
3.3 Results and Discussion  
 Design of ELISA tip adapter. We used 2 different designs for the pipette tips. The first was 
a single channel tip and the second was an 8-channel tip that fits 8-channel pipettes (Fig. 3.2A). 
Tips were designed in 123D® design software (Autodesk) and transferred to Form2® 
stereolithographic 3D printer where they were printed using Formlabs clear resin. The pipette tip 
has three main compartments, the pipette housing, immunoassay chamber and inlet cylinder. The 
inlet cylinder has outer diameter 3 mm and 15 mm length, suitable for drawing samples and 
reagents into the immunoassay chamber from ordinary microcentrifuge tubes. Total fill volume of 
immunoassay chamber and inlet cylinder is 50±3 µL (45 µL immunoassay chamber 5 µL inlet 
cylinder). The pipette housing compartment was designed as a conical cylinder to facilitate fitting 
onto different commercially available pipettes and was equipped with an overflow feature near the 
immunoassay chamber to prevent possible contamination of the pipette with reagents or samples 
(Fig. 3.1). Four different commercially available pipettes, Finnpipette® II, Eppendorf®, V-Pette®, 
and Acumax®, were tested. Designed tips snuggly fitted into these pipettes by applying less than 







Fig. 3.1 3D Design of ELISA tip platform. (A) A single pipette ELISA tip array, side view showing 
flow of reagents from bottom into the immunoassay chamber derived by vacuum suction applied 
through pipette attached at pipette housing on the top. (B) Front view, immunoassay chamber as a 
colorimetric/chemiluminescent viewing window. Inset showing sandwich immunoassay on the 
surface of immunoassay chamber. (C) Multi-chamber pipette ELISA tip used via a multichannel 
pipette for multianalyte or multiplex detection.  
 
Hydrogel film characterization. Chitosan is a naturally occurring polysaccharide that we 
found to adsorb strongly and irreversibly to the 3D-printed polyacrylate. A flat 1 x 1 cm 3D printed 
chip was coated with chitosan and used to estimate dry hydrogel film mass/cm2, swelling ratio %, 
and antibody coverage/cm2 in the ELISA tips. White light interferometry analysis of 3D printed 
surface coated with chitosan on showed large peaks of varying heights (5µm- 33 µm) intercalated 





It is likely that this roughness and chitosan swelling contributes to performance of the tip 
ELISA as it increases surface area for chitosan-Ab1 immobilization. Dry film loading capacity of 
the 3D printed chip was 0.10±0.01 mg chitosan/cm2. Film mass after hydration with water in a 
humidity chamber was 1.1±0.05 mg indicated swelling ratio % of 1100% from Eq 1. 47  
Swelling ratio (%)  =
Ws−Wd 
Wd
× 100 % (1)  
Fig. 3.2 Representation of sandwich immunoassays in ELISA tips with protocols: (A) Fully 
transparent 8-pipette 3D printed array loaded with food dyes; (B) Schematic illustration of pre-
coating steps showing immobilization of capture antibodies on immunoarray tip wall coated with 
chitosan followed by sandwich immunoassay and signal measurement for colorimetry and CL. (C) 




where Ws is weight of the swollen film and Wd is weight of dry chitosan film. Ab1 was anchored 
onto the chitosan film using glutaraldehyde as a cross linker for covalent immobilization (Fig. 
3.2B). Ab1 coverage calculated from BCA total protein assay was 10.0 ± 0.5 µg/cm
2 which is 
approximately 1.0x1013 antibodies/cm2 (SI, Fig. S4). We also estimated swelling of chitosan film 
after immobilizing Ab1. Dried chitosan films with Ab1 had mass 0.9±0.03 mg and the mass of the 
chitosan-Ab1 film after hydration increased to 5.5±0.04 mg for a swelling ratio of 600%. 
Fig. 3.3 Surface profile of 3D printed chip (A) Top View and (B) 3D view showing surface 
roughness with peaks of 5-33 µm intercalated by valleys that occupy ~10% of the 3D printed 
surface 
Single Protein Assays. Assay precision was evaluated at several analyte concentrations (n≥ 3) 
in calf serum (Fig. 3), which is an effective human serum surrogate for immunoassays.48  Fig. 3.4A 
shows reproducibility of colorimetry from 4 different tips at 1.3 and 12 ng/mL VEGF in calf serum, 
Fig. 3D shows images of colorimetric assays from 3 different tips at 1.3 and 5.5 ng/mL IGF-1 in 
calf serum, Standard deviations for each concentration were reproducible within ±5%. Day-to-
day standard deviations were less than ±7%. The assay was also done in cell phone-assisted mode. 
We utilized a simple photograph, and instant signal integration with a commercial color analytics 




reaction with increasing concentrations of VEGF and IGF-1. Images were captured and analyzed 
with the Color Grab mobile application. VEGF had a detection limit of 50 pg/mL and dynamic 
range 50 pg/mL to 10 ng/mL. Fig. 3.4C shows calibration curves obtained by plotting %K values 
as a measure of color intensity vs. VEGF concentration. IGF-1 had LOD of 20 pg/mL and dynamic 
range of 20 pg/mL to 5.5 ng/mL. Fig. 3F shows calibration curves obtained by plotting %K values 
measuring color intensity vs. IGF-1 concentration. Percent recoveries of VEGF from spiked 
human serum samples were found to validate accuracy of the cell phone-based assay and were 90-
110% (Table 1). Stability of antibodies immobilized in the tip was estimated by measuring the 
same concentration of IGF-1 (625 pg/mL) daily for tips stored at 4˚ C over 7 days.  Antibodies lost 
5% activity after 3 days and maintained 80% of initial activity after 7 days storage (Fig. 3.6).       
CL capture from tips by CCD camera was demonstrated using PSA as the test protein, Here, 
HRP oxidized femto-luminol to an excited state that decays and emits light that was captured and 
integrated over 120 s using a CCD camera in a dark box. Fig. 3.4H shows recolorized CL images 
that showing increased CL intensity with increasing PSA concentration. Fig. 3.4I is a calibration 
curve obtained by plotting CL intensities against PSA concentration. CL assay for PSA on calf 











Fig. 1.4 Single tip assays in calf serum using iphone and CCD camera imaging: (A) 
Reproducibility of colorimetric detection (n=4) for VEGF; (B) Change in colorimetric signal with 
increasing concentration of VEGF, (C) Calibration curve obtained via iphone imaging color 
intensity (K%) vs. [VEGF], (D) Reproducibility of colorimetric detection (n=3) for IGF-1; (E) 
Change in colorimetric signal with increasing concentration of IGF-1, (F) Calibration curve 
obtained via iphone K% vs. [IGF-1], (G) Raw CL images captured by CCD camera for PSA, (H) 
Recolorized images showing change in CL intensity vs. [PSA], (I) Calibration curve of relative 





Fig. 3.5 Screen shots from smartphone color analysis software “ColorGrap” of the ELISA in a Tip 
array. (A) Simple color analysis is showed step wise from upload to a photo to picking color to 
provide color analytics. (B) Color analysis sample output for 4 tip arrays as a part of reproducibility 






















Fig. 3.6 Antibody stability study. Colorimetric absorbance at 450 nm measured after running assay 
in tips stored at 4˚C for up to 7 days. Tips maintained 80% of its original activity after 7 days of 
storage (n=3) 
 
Multiplexed ELISA in a tip. The colorimetric assay was tested to simultaneously quantify 4 
proteins in undiluted calf serum. A multichannel pipette tip adapter (Fig. 3.2) was used with 2 
channels for each protein. Here we used a plate reader for absorbance detection to illustrate 
versatility of the approach. Fig. 3.7 shows calibration curves for the proteins, where standard 
deviation for each concentration was less than 15%. LODs were 5 pg/mL for PSA, 25 pg/mL for 
VEGF, 2.5 pg/mL for IGF-1 and 0.5 pg/mL for CD-14. Dynamic ranges were 5 to 10,000 pg/mL 






Fig. 3.7 Calibration curves for ELISA tip colorimetric multiplexed detection of (A) PSA, (B) 
VEGF, (C) IGF-1 and ((D) CD-14. Absorbance was measured at 450 nm in a plate reader (n=4). 
 
Recoveries from spiked, diluted human serum were measured to validate accuracy of 
multiplexed ELISA in a tip. Human serum was diluted 100-fold before spiking to bring native 




estimate recoveries from spiked human serum. Recoveries estimated after subtracting the signals 
from control serum and were in an analytically acceptable range49 of 100±20% (Table 1). 
Table 3.1. Spike-recovery results from single and multiplex immunoassays in human serum.   
 
Patient sample analyses. PSA, IGF-1 and CD-14 represent promising biomarkers for prostate 
cancer diagnostics.50,51,52 and were measured in 13 patient serum samples by multiplexed analysis. 
The sample cohort consisted of 3 normal cancer-free individuals, 5 samples collected from patients 
with indolent prostate cancer (Gleason score <7) and 5 samples from patients with aggressive 
prostate cancer (Gleason score >7). Samples were analyzed by colorimetric tip ELISA and results 








Cell phone-assisted  
Single Tip Assay 
VEGF 100 107 (± 6) 107 (± 7) 
1000 950 (± 84) 95 (± 9) 
4000 4133 (± 454) 103(± 7) 
Colorimetric 
8 Chamber Tip Assay 
 
 
PSA 20 21 (± 1.5) 105 (± 7) 
300 296 (± 38) 98 (± 13) 
2000 2397 (± 144) 119 (± 6) 
VEGF 125 122 (± 15) 98 (± 12) 
500 436 (± 42) 87 (± 9) 
2000 2051 (± 287) 102 (±14) 
IGF-1 125.0 121 (± 16) 100 (± 13) 
800 925 (± 138) 98.5 (± 15) 
2000 2134 (± 320) 93 (± 15) 
CD-14 10 11 (± 0.89) 113 (± 7) 
500 450 (± 43) 90 (± 9) 
5000 5402 (± 486) 108 (± 9) 




were compared to both micro-well plate ELISA (Table 3.2-3.4) and an established validated 
microfluidic electrochemical assay.  
 
 
Table 3.2. Comparison between calculated conc. of PSA in patient samples between Micro-well 









Cancer Status  Patient 
Sample Code 
PSA 
Tip-ELISA Micro-well ELISA 
Found Conc. 
ng/mL 
St. Dev. Found Conc. 
ng/mL 
St. Dev. 
Controls C3 0.21 0.00 0.72 0.08 
C8 0.49 0.04 0.45 0.03 
C18 0.28 0.01 1.23 0.17 
Indolent Prostate 
cancer  
(Gleason score <7) 
23 1.01 0.45 8.87 1.15 
24 0.31 0.03 0.23 0.02 
25 2.81 0.03 0.72 0.06 
27 4.77 0.75 10.70 1.18 
28 1.27 0.01 1.58 0.16 
Aggressive 
Prostate cancer  
(Gleason score >7) 
1114 3.09 0.14 2.54 0.15 
1115 9.45 17.20 10.81 1.41 
1123 7.90 18.10 2.34 0.05 
1136 1030.67 33.74 800.05 56.00 




Table 3.3. Comparison between calculated conc. of IGF-1 in patient samples between Micro-
well ELISA and Tip-ELISA 
 
Table 3.4. Comparison between calculated conc. of CD-14 in patient samples between Micro-
well ELISA and Tip-ELISA 
 
Cancer Status  Patient 
Sample Code 
IGF-1 
Tip-ELISA Micro-well ELISA 
Found Conc. 
ng/mL 
St. Dev. Found Conc. 
ng/mL 
St. Dev. 
Controls C3 6.99 0.04 4.27 0.05 
C8 5.97 0.07 4.78 0.04 
C18 4.81 0.00 5.02 0.07 
Indolent Prostate 
cancer  
(Gleason score <7) 
23 2.77 0.12 2.35 0.02 
24 31.45 0.40 26.83 0.13 
25 2.42 0.01 2.28 0.00 
27 1.83 0.00 2.07 0.01 
28 2.32 0.03 2.13 0.01 
Aggressive 
Prostate cancer  
(Gleason score >7) 
1114 24.84 0.15 24.65 0.35 
1115 29.36 0.85 29.37 0.21 
1123 11.13 0.00 9.60 0.07 
1136 2.46 0.71 2.16 0.02 
1138 3.24 0.47 2.30 0.18 
Cancer Status  Patient 
Sample Code 
CD-14 
Tip-ELISA Micro-well ELISA 
Found Conc. 
ng/mL 
St. Dev. Found Conc. 
ng/mL 
St. Dev. 
Controls C3 0.17 0.01 0.35 0.03 
C8 0.26 0.01 0.53 0.07 
C18 0.76 0.07 0.87 0.07 
Indolent Prostate 
cancer  
(Gleason score <7) 
23 0.66 0.01 1.07 0.10 
24 0.62 0.03 1.25 0.04 
25 1.14 0.03 1.20 0.08 
27 4.90 0.20 4.82 0.05 
28 1.48 0.10 1.12 0.13 
Aggressive 
Prostate cancer  
(Gleason score >7) 
1114 2855.21 6.75 2220.26 310.84 
1115 3006.53 9.82 3053.69 335.91 
1123 2530.48 20.15 2434.10 121.70 
1136 602.40 33.24 610.16 42.71 




Tip ELISA gave excellent correlation with microwell ELISA and the electrochemical assay as 
demonstrated by correlation coefficients and slopes near 1.0 and intercepts near zero. Correlation 
coefficients with the electrochemical assay were 0.999 for PSA, 0.991 for IGF-1, and 0.992 for 
CD-14 and slopes were 1.17 for PSA, 0.87 for IGF-1 and 1.23 for CD-14 (Fig. 3.8).  
Fig. 3.8 Linear correlations for pipette tip ELISA vs. referee assay for (A) PSA, (B) IGF1, and (C) 
CD14, quantified in ng/mL (n=3) in patient samples. Insets show low concentration ranges. 
Correlation coefficients with micro-well plate ELISA were 0.999 for PSA, 0.986 for IGF-1 
and 0.981 for CD-14 and slopes were 0.775 for PSA, 0.949 for IGF-1 and 0.917 for CD-14 (Fig. 
3.9).  
Fig. 3.9 Linear correlations for pipette tip ELISA vs. micro-well plate ELISA for (A) PSA, (B) 









































IGF-1 concentration in 10X diluted serum samples was also estimated using iphone imaging 
colorimetric assay and had correlation coefficient of 0.973 vs. conventional ELISA with slope of 
0.978 (Fig. 3.10 and Table 3.5). Linear correlations of tip ELISA with the referee methods gave 
correlation coefficients for the three proteins >0.90, slopes close to unity, and intercepts close to 
zero. Insets show correlations in the lower concentration range.  
 
Table 3.5. Comparison between calculated conc. of IGF-1 in patient samples between Micro-








Cancer Status  Patient 
Sample Code 
IGF-1 
Tip-ELISA Micro-well ELISA 
Found Conc. 
ng/mL 
St. Dev. Found Conc. 
ng/mL 
St. Dev. 
Controls C3 4.78 0.15 4.27 0.05 
C8 4.90 0.10 4.78 0.04 
C18 5.26 0.16 5.02 0.07 
Indolent Prostate 
cancer  
(Gleason score <7) 
23 1.81 0.06 2.35 0.02 
24 28.68 0.78 26.83 0.13 
25 2.29 0.03 2.28 0.00 
27 1.46 0.19 2.07 0.01 
28 2.29 0.13 2.13 0.01 
Aggressive 
Prostate cancer  
(Gleason score >7) 
1114 19.39 0.84 24.65 0.35 
1115 31.16 2.67 29.37 0.21 
1123 8.45 0.24 9.60 0.07 
1136 1.60 0.10 2.16 0.02 





Fig. 3.10 Linear correlations for smart phone pipette tip ELISA vs. referee assay for IGF-1, 





While the number of samples is much too small for definitive conclusions, receiver operator 







Fig. 3.11 Receiver operating characteristic (ROC) curve for PSA (blue), IGF-1 (red), CD-14 
(orange) and sum of the values of the 3 biomarkers (green). Data collected from analysis of 13 real 
human samples consisting of 3 controls and 10 prostate cancer samples. AUC were 0.967 for PSA, 
0.700 for IGF-1, 0.833 for CD-14 and 1.000 for the sum of the concentrations of the 3 biomarkers. 
 
PSA show moderate increases for cancer and aggressive cancer samples, while CD-14 shows 
very large increase for aggressive prostate cancer. In addition, clustered multiple variables box 











Fig. 3.12 Box-and-whisker plots representing amounts of each biomarker in the human samples: 
(A) PSA and IGF-1 serum level comparison; (B) CD-14 serum level comparison between control 
group (blue), indolent prostate cancer group (yellow), and aggressive prostate cancer group (red). 
Results obtained from tip-based assay using colorimetric procedures (n=3).      
 
Results above demonstrate a novel ELISA in a tip strategy utilizing 25% smaller reagent and 
samples volumes and 25% shorter assay time than traditional ELISA (Table 3.6). ELISA in a tip 
offers opportunities that can allow decreases in instrumentation cost and size, e.g. by using cell 
phone data capture and analysis. The latter approach also facilitates electronic reporting to relevant 
health care providers and the patients themselves. We demonstrated sensitive detection of 4 cancer 
biomarkers proteins simultaneously with ELISA in a tip. Users with pipette use knowledge or 




Pipetting speed and accuracy may slightly affect the performance of the assay, and we did not 
notice significant variation between users. We believe developing future automated systems 
engineered for the pipette-tip assay may eliminate user-to-user variation.   
 
Antigen-antibody reactions at a solid-liquid interface as in microplate ELISA are limited by 
diffusion and antigens, available to interact with immobilized antibodies, are depleted with 
time.54,55 Reagent volume/surface area ratios are 131 µL/cm2 for microwells and 31 µL/cm2 for 
the pipette tip chamber. This 4-time lower volume/surface area ratio improves Ag-Ab interaction 
kinetics reflected in better sensitivities and shorter assay times. 
The roughness of the 3D printed surface (Fig. 3.3) of the tip and the use of a highly swelled 
hydrogel also contribute to effective surface area, which increases the antibody surface loading 
capacity.56 Antibody loading in 3D printed tips was 10.0±0.5 µg/cm2 which is 15-50 times higher  
than reported capacities for commercial microplates (200-650 ng/cm2).57 This high surface loading 
helped reducing assay time while maintaining similar sensitivity to conventional ELISA. In 
addition, covalent immobilization of antibodies onto chitosan hydrogel maintains high activity 
compared to documented loss of activity for passively adsorbed antibodies on polymers surfaces 










Table 3.6. Comparison between ELISA in a TIP vs. microplate ELISA  
  













Development & Quench 
Detection 
Approx. total wash time 


























150 min  






Reagent/sample volume 50 µL for sample 
and wash 
50 µL for 
sample and 
wash 
50 µL for 
sample and 
wash 
150 µL (sample) 300 µL 
(wash) 
LOD (pg/mL) &  
Dynamic range (pg/mL) 
PSA - 5 & 5-10000 
VEGF – 25 & 50 - 
10000 
IGF-1 4 & 4 – 8000 
CD-14 - 0.5 & 1-
10000 
PSA 1 & 1-
100,000  
IGF-1 20 & 
20 – 5500 
VEGF 50 & 
50 - 10000 
PSA - 900 & 900 - 60000 
VEGF – 25 & 35 - 2000 
IGF-1 – 100 & 100 - 8000 
CD-14 - 62 & 62 - 4000 
Assay cost per 
microwell 




$4.14/ micro well 
(Human PSA ELISA Kit – 
$398) 
Required Instrument Plate reader CCD Camera Smart phone No 









The transparent tips 3D printed with a low-cost stereolithographic printer was shown to be 
applicable to colorimetric (Fig. 3.4) and CL detection. CL assays detected of PSA from complex 
serum matrix with detection limits of 1 pg/mL (Fig. 3.4). No additional steps or modifications are 
required for CL detection compared to colorimetric assays. CL arrays can be easily integrated with 
a cell phone making them available for resource limited settings.61,62 The “ELISA in a Tip” 
platform was also customized to multiplex multiple analytes and multi-sample assays 
simultaneously. CAD files for ELISA tip printing can be found at 
https://rusling.research.uconn.edu/research/3d-printing-designs/. The simple design facilitates 
extension for multichannel pipettes with 12, 16, 48 & 64 channels.  
Cell phone interfacing can enable 3D printed tip arrays for resource limited settings. Using 
free, commercially available, software ‘Color Grab’ we demonstrated sensitive detection of 
colorimetric signals right directly from the tip array and validated accuracy of detection with 
spiked human serum (Table 3.1) and analyzing real serum samples (Table 3.5). Interfacing cell 
phones could also help in telemedicine to establish networks between assay technician, centralized 
labs and physicians. At rural sites in developing countries where availability of resources for 
traditional ELISA may be limited, cell phone analysis of Tip ELISA can be used at a fraction of 
the cost and time of standard ELISA kits. 
In summary, we describe and demonstrate above an “ELISA in a tip” immunoassay tool 
designed by 3D printing immunoassay tips for conventional pipettes. “ELISA in a tip” can provide 
better LODs and dynamic range than microwell ELISA kits, at lower cost, sample volume, and 
assay time. Multiple signal detection strategies and multiplexed detection are accommodated. Cell 
phone integration enables the prospect of low-cost detection diagnostics and telemedical 




sensitive, multiplexing, immunoassay with tips that any lab with a stereolithographic 3D printer 
can access, with capability that is faster and cheaper than conventional ELISA and may be 
particularly useful in resource-limited venues. 
3.4 Materials and Methods 
Materials. All reagents and chemicals were of analytical grade. Chitosan (low molecular 
weight) and glutaraldehyde were from Sigma Aldrich. Blocker casein in PBS buffer was from 
Thermo Fisher.  ELISA kits for Prostate Specific Antigen (PSA) (DY1344), Vascular endothelial 
growth factor (VEGF) (DY293B), Insulin-Like Growth Factor 1 (IGF-1) (DY291) and Cluster of 
Differentiation-14 (CD-14) (DY383) were from R&D systems. Colorimetric signals were 
generated using R&D systems substrate reagent pack with tetramethylbenzidine (TMB) color 
reagent and peroxide mixed immediately before use. Chemiluminescence (CL) was generated 
using Thermo Fisher Supersignal® West Femto chemiluminescent substrate, with luminol and 
peroxide mixed right immediately before use.  All colorimetric measurements were performed 
after transferring the solutions after color was developed to microplate and absorbance was 
measured using Synergy® HTX plate reader. CL was measured in pipette tips using a Syngene® 
dark box with CCD camera. Images were processed using GeneSnap® software. Mobile phone 
image processing was done using an android/iPhone compatible application Loomatix 
ColorGrab®. Human prostate cancer patient serum samples and controls were from George 
Washington University (GWU) Hospital under IRB ethical approval. 
Antibody immobilization. Inner walls of tips were coated with a polymeric hydrogel layer of 
chitosan by dispensing 50 µL of 0.25% chitosan in 0.05 M HCl (pH.4.0) solution into the pipette 
tip and incubating 3 hrs. Solution was then removed and pipette tips allowed to dry under vacuum 
at room temperature for 3 hrs, forming a thin, stable film of chitosan onto the inner walls. Amine 




in phosphate buffer (PBS, pH.7.4), then incubated for another 3 hrs. Glutaraldehyde solution was 
then removed and tips were washed with PBS. 50 µL of antibody solution at desired concentrations 
was pipetted into the tips, which were then incubated overnight (Fig. 3.2B). To compare to 
microwell plate ELISA, all antibodies were used at concentrations recommended by ELISA kit 
suppliers. After incubation, antibody solutions were removed, and tips were washed with 
phosphate buffer- 0.05% Tween 20 solution (PBS-T20, pH.7.4) to remove unbound antibodies and 
inhibit non-specific binding (NSB). 
Chitosan layers were characterized by coating a 1 x 1 cm 3D printed chip with chitosan using 
white light interferometry and a Filmetrics Profilm3D profilometer equipped with a 20X Mirau 
objective and Profilm software. Antibody (Ab1) coverage on the flat 3D printed chip was estimated 
using the bicinchoninic acid (BCA) total protein assay. 63 Chitosan chips were incubated with 100 
µL 3% glutaraldehyde, washed and incubated with 100 µL of 10 µg/mL anti-PSA antibodies 
overnight. Chips were then washed with PBS-T20 and incubated with 100 µL of BCA reagent 
(Thermo Fisher®) at 37˚ C for 2 hrs. Reagent was then transferred to a microplate where 
absorbance was measured at 562 nm.  The absorbance was then used to estimate total amount of 
antibodies on the chip from a calibration curve for standard anti-PSA. 
Colorimetric assay. Tips decorated with Ab1 were filled with 50 µL standard protein or 
sample solution and incubated 30 min. Tips were then washed 3X with PBS-T20, 50 µL of 
biotinylated detection antibody (Ab2) solution in 1% casein in PBS solution were pipetted in and 
incubated 20 min. Unbound Ab2 were removed by washing 3X with PBS-T20, tips were filled 
with 50 µL streptavidin horseradish peroxidase (ST-HRP) diluted according to vendor 
specifications in 1% BSA in PBS and incubated 15 min. Tips were washed 3X with PBS-T20 and 




peroxide solution according to vendor specifications and incubated 12 min. Finally, solutions with 
developed color were transferred from tips into a 96 well microplate and filled with 50 μL of 2N 
sulfuric acid stop solution, and absorbance at 450 nm was measured using a microplate reader (Fig. 
3.2C).        
 Chemiluminescence (CL) assay. Procedures were the same as for colorimetry except for the 
CL development and detection. Supersignal® West Femto reagent was used to develop CL that 
was recorded with a CCD camera in a dark box. Tips with sandwich immunocomplex decorated 
with HRP were filled with luminol reagent prepared by mixing equal volumes of luminol/enhancer 
substrate and hydrogen peroxide solution according to vendor specifications. Tips with CL reagent 
were then immediately placed into the dark box and images captured over 120 s (Fig. 3.2C). 
Images were analyzed using GeneTools® software (Syngene) to convert to relative CL intensity.  
Cell phone-assisted image capture. Using colorimetric assay procedure, images of the 
developed blue color after incubation of TMB in each tip were captured using an Android cell 
phone camera with 12 megapixels resolution. Images of each tip were analyzed individually using 
free mobile app ColorGrap® from Loomatix available for both android cell phones and iPhones. 
ColorGrap uses image digitizer software to convert color intensity into a set of numbers based on 
the color composition and intensity of the specific image (Fig. 3.2C). K% values from analysis of 
each captured image were used to describe the intensity of the blue color developed since it showed 
the best correlation with color development.  
Assay Validation and patient samples analysis. Assays were validated by measuring 
recoveries of biomarker proteins in spiked human serum samples. 100X diluted sterile, filtered 
human serum from human male AB plasma (Sigma®) was spiked with different concentrations of 




concentrations were done in triplicate and concentrations were calculated after subtracting the 
signal from diluted human serum control. In addition, 13 human samples (3 controls, 5 indolent 
prostate cancer patients and 5 aggressive prostate cancer patients) were analyzed for 3 prostate 
cancer biomarker proteins, PSA, IGF-1 and CD-14, using the colorimetric assay. Patient samples 
were diluted 10x in PBS buffer for analysis of PSA and IGF-1 and 100x for analysis of CD-14 in 
order to bring biomarkers into dynamic range of the assays. Diluted samples were incubated in 
pipette tips for 30 min, washed 3x with PBS-T20 followed by incubation with 50 µL optimized 
Ab2 solution. The same procedure described for colorimetric assays was followed in patient sample 
analysis using same R&D ELISA kits for tip assay, electrochemical and microwell plate ELISA. 
The same patient samples dilutions were used for traditional micro-well plate ELISA. Assay 
results were well correlated with those obtained from micro-well ELISA and well-established 
electrochemical immunoassay developed in house and similar to a published procedure. 35,36  
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Cancer Metastasis Biomarker Detection at Single Cell Levels using a 
3D-Printed Microfluidic Immunoarray 
 
4.1 Abstract 
 A microarray device capable of lysing cells and quantifying biomarker proteins released was 
designed and 3D-printed. Cell samples were lysed on-chip using RIPA lysis buffer augmented 
with 2 s pulse of a 50 KHz cell disruptor. Detection of desmoglein 3 (DSG3), a metastatic 
biomarker for head and neck squamous cell carcinoma (HNSCC), at single cell levels in multiple 
oral cancer cell cultures was demonstrated. The chip was equipped with a lysis chamber containing 
lysis buffer and sonication probe and reagent compartments that deliver samples and reagents to 
detection chambers. A sandwich immunoassay protocol captures target analytes in specified 
detection chambers decorated with specific capture antibodies immobilized on a hydrogel 3D 
chitosan film. Analytes were labeled with biotinylated secondary antibodies, which then capture 
streptavidin poly[horse radish peroxidase] (Poly-HRP). Chemiluminescence was then generated 
by delivering enhanced luminol reagent including H2O2 and captured with a CCD camera. 
Analytes include DSG3, a biomarker protein that resides in HNSCC cells that invade lymph nodes 
in metastasis, vascular endothelial growth factor-C (VEGF-C) as a positive control overexpressed 
in HSNCC, and beta-tubulin (β-Tub) as a loading control to estimate the number of cells in each 
sample. Detection limits were 0.10 fg/mL for DSG3, 0.20 fg/mL for VEGF-C and 0.20 fg/mL for 
β-Tub. Dynamic ranges were 0.10 – 100 fg/mL for DSG3, 0.20 – 200 fg/mL for VEGF-C and 0.10 
– 100 fg/mL for β-Tub. With reported detection limits we were able to quantify proteins from a 
single cell lysate. Strong correlation between results obtained from on-chip cell lysis and 





4.2 Introduction    
Ninety percent of all cancer deaths are caused by metastasis (spreading) of original tumors.1 It 
is well established that early detection leads to improved survival of cancer patients,2 which holds 
for metastasis as well.3 In this paper, we present a new automated microfluidic immunoarray to 
enable rapid, ultrasensitive detection of metastasis biomarkers.   
While the approach reported here is applicable to any cancer and virtually any type of tissue, 
we focus here on desmoglein 3 (DSG3) as a high quality membrane-bound diagnostic biomarker 
for lymph node metastasis in oral cancer, or head and neck squamous cell carcinoma (HNSCC). 
4,5 We recently established membrane protein DSG3 as a biomarker for occult lymph node 
metastasis of HNSCC.6 DSG3 is highly expressed in metastatic oral cancer cells that have invaded 
neck lymph nodes, but not found in non-invaded lymph nodes.7  HNSCC is one of the ten most 
common cancers worldwide, and accounts for ~10,000 deaths/year in the USA, with a 57% five 
year survival rate for newly diagnosed patients.8  Oral cancer has an unusually high tendency to 
metastasize due to an extensive neck lymphatic network nearby.9-12 Incidence of occult lymph 
node metastasis ranges between 10 - 50%.13-19Thus, rapid, sensitive diagnosis of lymph node 
metastasis is essential for HNSCC prognosis and key for clinical staging and treatment 
decisions.14,10,20,  
Diagnosis of neck lymph node metastasis in HNSCC patients is currently addressed by 
pathological tests.21-23 The current histopathological hematoxylin-eosin (H&E)-
immunohistochemistry (IHC) assay can detect lesions <0.2 mm in lymph nodes to assess 
metastatic oral cancer, 30b but requires days and cannot be used for in-operative staging. Modern 




early metastasis. Real time (RT)-PCR methods can detect metastasis, but is relatively expensive, 
requires a skilled technician, and lacks single cell sensitivity. 27-29  Pathological evaluation of lymph 
nodes remains the preferred option, despite many false negatives due to failure to detect lesions 
<0.2 mm. 30-32 In addition, high incidence of HNSCC metastasis dictates that most node-negative 
patients undergo elective neck dissection to fully remove lymph nodes for assessment, resulting in 
potentially debilitating post-surgical overtreatment in over half of HNSCC patients.33,34 Thus, there 
is an urgent need for fast, accurate, and ultrasensitive in-operative detection of metastatic oral 
cancer. 
Microfluidic sensors offer a fast and reliable platform for ultrasensitive automated multi-
protein assays.35 We used an amperometric  microfluidic immunosensor previously to investigate 
DSG3 as an oral cancer biomarker for metastasis in lymph nodes.6 Other microfluidic 
immunosensors using electrochemical, electrochemiluminescent (ECL), and chemiluminescent 
(CL) detection have been developed to measure multiple protein and peptide biomarkers for 
diagnostics.36-39 Also, desktop 3D printing now offers a simple, low cost, tool for development and 
fabrication of high performance microfluidic arrays.40-43 
In this paper, we describe a 3D printed microfluidic array for ultrasensitive CL detection of 
DSG3 at single cell levels. Intact cell samples are introduced into the device and are lysed by 
ultrasonic-assisted chemical lysis. Detection chambers were coated with a hydrogel chitosan film 
that swells into a 3D structure where capture antibodies were immobilized. This 3D structure of 
chitosan helped increase antibody surface coverage which in addition to using poly HRP and 
ultrasensitive femto-luminol reagent helped reaching ultra-high assay sensitivity (<1 fg/mL). For 
comprehensive assessment of the samples, vascular endothelial growth factor-C (VEGF-C), a 




and beta-tubulin (β-Tub) was measured as a marker of the number of lysed cells (Scheme 4.1). 
DSG3 was detected at the single cell level with limit of detection (LOD) 0.10 fg/mL and 0.25 
relative CL unit (CLU)/ log(fg/mL) sensitivity. VEGF-C had LOD 0.10 fg/mL and sensitivity of 
0.08 CLU/log (fg/mL) and β-Tub had a 0.20 fg/mL LOD and 0.05 CLU/log (fg/mL).   
 
Scheme 4.1. Assay protocol and chemiluminescence signal generation using Femto-luminol 
reagent and re-colorized image of the signal captured using CCD camera   
4.3 Materials and Methods 
Materials. All reagents and chemicals were of analytical grade. Chitosan (low molecular 
weight) and glutaraldehyde were from Sigma Aldrich. Blocker casein in PBS buffer was from 
Thermo Fisher. ELISA kit for Vascular Endothelial Growth Factor-C (VEGF-C) (DY752B) was 
from R&D Systems. Human Desmoglein3 (DSG3) monoclonal antibody (MAB1720), human 
DSG3 biotinylated polyclonal antibody (BAF1720), recombinant human DSG3 chimera protein 
(1720-DM) and bovine serum albumin (BSA) were purchased from R&D Systems. Monoclonal 
[EP1331Y] beta-Tubulin antibody, biotinylated monoclonal [BT7R] beta-Tubulin antibody and 




mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1.0% Igepal CA-630 (NP-40), 0.5% sodium 
deoxycholate, and 0.1% sodium dodecyl sulfate, and 2% Halt Protease and Phosphatase Inhibitor 
Single-Use Cocktail) was from Sigma Aldrich. Chemiluminescence (CL) was generated using 
Thermo Fisher Supersignal® West Femto chemiluminescent substrate, containing femto-luminol 
and hydrogen peroxide mixed immediately before use. Streptavidin-Poly(Horseradish Peroxidase) 
(Poly-HRP80) conjugate was obtained from Fitzgerald®. CL was measured using a Syngene® 
dark box with CCD camera. Images were processed using GeneSnap® software. Phosphate buffer 
saline (PBS) pH 7.4 was 0.01 M sodium phosphate in 0.14 M NaCl, 2.7 mM KCl and phosphate 
buffer saline-tween20 (PBS-T20) was 0.01 M sodium phosphate in 0.14 M NaCl, 2.7 mM KCl 
and 0.5% Tween-20. Cell lines CAL27 was from ATCC (Va), HN12, HN13 and HN30 were 
provided by Dr. Silvio Gutkind, University of California San Diego, and cultured Dulbecco's 
modified Eagle medium supplemented with 10% fetal bovine serum at 37°C in the presence of 5% 
CO2 as described previously.45 
Microfluidic chip design. In order to reduce interaction between different reagents and 
samples before reaching the detection compartment, a five-inlet microfluidic chip design was 
adopted. The chip was equipped with five 80 μL chambers for sample, biotinylated antibodies, 
poly-HRP, CL reagent and wash buffer (PBS-T20) sequentially. An 8-chamber detection 
compartment for detection of the 3 selected biomarkers in duplicates and 2 chambers for BSA 
negative control each chamber volume capacity was 8 μL. The chip was connected to 5 
programmable peristaltic micropumps (Takasago Fluidic Systems, RP-Q1.2N-P20Z) controlled 
by an Arduino® microcontroller (Fig. 4.1). The micropumps were housed in a 3D printed support 
that also accommodate an ultrasonic probe (Sonic Soak) placed directly under the sample chamber.       






Fig. 4.1 Device design (A) Microfluidic chip design with 5 inlets connected to peristaltic 
micropumps, sample and reagent chambers with capacity of 80± 5 μL, and 8 detection chambers 
with 8±1 μL capacity each. (B) Microfluidic chip mounted on the support equipped with the 
sonication probe and connected to micropumps controlled by Arduino microcontroller. (C) 
programmable micropumps connected to microfluidic chip and controlled by an Arduino 
microcontroller. (D) 3D printed support with the microfluidic chip housing suiting the sample 






Antibody immobilization. Capture antibodies (Ab1) were immobilized on the inner walls of 
each detection chamber using previously reported chitosan/glutaraldehyde chemistry.46 Briefly, a 
thin film of chitosan on the inner walls of detection chambers was formed by adding 8 μL of 0.5 
mg/mL chitosan in 0.05 M HCl (pH 4.0) into each detection chamber and were allowed to incubate 
for 3 hrs. Chitosan solution was drained out and the liquid film was dried under vacuum at RT 
overnight. 8 μL of 3% glutaraldehyde in PBS (pH 8.0) was added to detection chambers for 3 hrs, 
washed with DI water and 8 μL of capture antibodies at pre-optimized concentrations were added 
and incubated overnight. Unbound antibodies were washed with PBS-T20 and detection 
compartment was incubated with 1% casein blocker buffer for 1 hr. Detection compartment was 
washed with PBS-T20 and chips were stored at 4˚C until used.                  
Multiplexed biomarker chemiluminescence assay. 80 μL of standards with different 
concentrations of biomarker panel prepared in RIPA buffer/5% calf serum to mimic cell lysate 
surrogates were introduced into sample compartment. Samples were delivered to detection 
compartment by activating sample pump for 25s at a flow rate of 200 μL/min, incubated for 20 
min, and washed by activating the PBS-T20 pump for 1 min a flow rate of 200 μL/min. 
Biotinylated detection antibodies (Ab2) were delivered to detection compartment by activating 
Ab2 pump for 20 s at 200 μL/min, incubated for 15 min and washed with 200 μL PBS-T20 by 
activating PBS-T20 pump for 1 min. Poly-HRP was flowed to detection compartment by activating 
HRP pump for 20s, incubated for 10 min, and washed with 200 μL of PBS-T20. Finally, femto 
luminol chemiluminescence reagent was delivered to detection compartment and 




Assay Validation. To assess the accuracy of assay, estimated concentration of each biomarker 
from spiked protein depleted cell lysates. Same chemiluminescence procedures were adapted to 
estimate concertation of each protein biomarker.      
Cell culture. Cell cultures, HN12, HN13, HN30 and CAL27 were analyzed for the selected 
biomarker panel. Cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) 
in presence of 5% CO2 at 37˚C. Cells with culture medium were collected by mechanical 
separation of adherent cell layer from culture plates and number of cells per mL were estimated 
using manual cell counting.  
Biomarker quantification form offline cell lysates. Offline cell lysis was used as standard 
method to prepare cell lysates that was introduced directly into the sample chamber and delivered 
right away to detection compartment. Cells were lysed by incubation with RIPA lysis buffer for 
20 min with intermittent vertexing. Cell lysates originally estimated to have 1 x 106 cells/mL were 
diluted 105X before introducing 80 μL of lysate (~ 1 cell contents) into the sample chamber in 
order to bring biomarkers into the working concentration of the assay. Same chemiluminescence 
assay procedures were followed.  
Biomarker quantification after online cell lysis. Collected cells with culture medium was 
diluted 104 times and 5 μL of the dilute cell solution was introduced into the sample chamber 
containing 75 μL of RIPA lysis buffer. Once introduced, the ultrasonic probe (50 KHz) was 
activated for 2s to mix the cells with the lysis buffer and augment the lysis process. Solution was 
kept in the sample compartment for 20 min, delivered to detection compartment and incubated for 






Chitosan film characterization. Thin chitosan film formed on the inner wall of the detection 
chamber offer an expandable hydrogel layer allowing anchoring of massive numbers of Ab1. The 
3D printed surface coated with chitosan has large peaks with different heights (5-33 μm) 
intercalated with approximately 10% valleys as shown in white light interferometry images (Fig. 
2) The chitosan film after swelling had ~ 600% water of its total mass.46 In addition, the volume 
of chitosan film increased approximately 1000% after swelling (Fig. 4.2). This huge increase in 
volume and mass with the surface roughness allowed the immobilization of approximately 
1.0x1013 antibodies/cm2.  
 
 
Fig. 4.2 White light 
interferometry surface profile of 
chitosan coated 3D printed chip 
(A) top view (B) Side view. 
Digital microscope images of side 
view of chitosan hydrogel 
hemisphere loaded with 
methylene blue dye (C) with 
water, (D) after drying. Digital 
microscope images of top view of 
chitosan hydrogel hemisphere 
loaded with methylene blue dye 
(E) with water, (F) after drying. 
Images show ~ 1000% increase in 
hemisphere volume after wetting 




Multiplexed biomarker assay. Capture and detection antibody concentrations along with 
incubation time of sample and detection antibodies in detection compartment were optimized for 
highest signal to noise ratio (Fig4.3-Fig. 4.6).  
Fig.  4.3 Optimization of the immobilized capture antibody (Ab1) concentration for (A) DSG3, (B) 
VEGF-C and (C) Beta Tub. Other experimental parameters were held constant while testing 
different Ab1 concentrations. Signals were generated after flowing 100 μL west femto® luminol 
chemiluminescence substrate and images were captured for 15s using a CCD camera in dark box 
and relative intensity were calculated using GeneSnap® software    
Fig.  4.4 Optimization of the immobilized detection antibody (Ab2) concentration for (A) DSG3, 
(B) VEGF-C and (C) Beta Tub. Other experimental parameters were held constant while testing 
different Ab1 concentrations. Signals were generated after flowing 100 μL west femto® luminol 
chemiluminescence substrate and images were captured for 15s using a CCD camera in dark box 





Fig.  4.5 Optimization of the incubation times for different antigens while stabilizing other 
experimental parameters (A) DSG3, (B) VEGF-C and (C) Beta Tub. Signals were generated after 
flowing 100 μL west femto® luminol chemiluminescence substrate and images were captured for 
15s using a CCD camera in dark box and relative intensity were calculated using GeneSnap® 
software    
Fig.  4.6 Optimization of the incubation times for Ab2 for (A) DSG3, (B) VEGF-C and (C) Beta 
Tub while stabilizing other experimental parameters. Signals were generated after flowing 100 μL 
west femto® luminol chemiluminescence substrate and images were captured for 15s using a CCD 
camera in dark box and relative intensity were calculated using GeneSnap® software    
 
Preoptimized assay parameters were used to quantify the selected panel of biomarkers to assess 
the metastasis of HNC. Standards were prepared in RIPA lysis buffer spiked with 5x diluted calf 
serum to mimic the cell lysate matrix. Fig. 4.7 show the calibration curves for the selected 




detections (LOD) were 0.10 fg/mL for DSG3, 0.20 fg/mL for VEGF-C and 0.20 fg/mL for β-Tub 
and dynamic ranges were 0.10-100 fg/mL for DSG3, 0.20-200 fg/mL for VEGF-C and 0.20-100 
fg/mL for β-Tub. The ability to detect sub femtogram levels of DSG3 and VEGF-C promise single 
cell discovery in analyzed samples. DSG3 had expression levels of 90-250 fg/tumor cell which 
lies perfectly above the assay detection limit. Similarly, VEGF-C is secreted into the cell culture 
media and expressed in levels higher than 100 pg/mL which also perfectly fit the assay dynamic 
range after dilution.  
 Fig. 4.7 Calibration curves obtained with the microfluidic microchip for (A) DSG3, (B) VEGF-C 
and (C) β-Tub. Cl signal was captured using a=CCD camera for 15 s. (n=4)  
Effect of Sonication. To test the effect of sonication on the lysis efficiency, lysis step was 
performed in presence of lysis buffer without sonication and compared to applying 2s and 10s 
sonication. In addition, lysis step was also tested with PBS buffer (without the use of lysis buffer) 
in absence of sonication and with 2s and 10s sonication. In absence of sonication, both lysis buffer 
and PBS buffer samples showed concentration of VEGF-C (10±4.8 pg/mL) with negligible 
response for DSG3 and β-Tub. With 2s sonication in lysis buffer, DSG3 and β-Tub showed 50-
150 fg/mL concentration with VEGF-C concentration of 11±3.2 pg/mL. PBS buffer with 2s 
sonication also had a relatively significant levels of both DSG3 and β-Tub (2-10 fg/mL) but still 




noticeable change in both biomarkers’ concentration compared to 2s sonication while 10s 
sonication in PBS buffer showed an increase in DSG-3 and β-Tub compared to 2s sonication (Fig. 
4.8).           
Fig.  4.8 Effect of sonication time on the extraction and quantitation of (A) DSG3, (B) VEGF-C, 
and (C) β-Tub in RIPA lysis buffer (blue line) and PBS buffer (Red dotted line) (n=4) 
 
Assay validation.  Selected concentrations of the biomarker panel were analyzed on the same 
day using different chips to estimate intra-day assay variation. Calculated relative standard 
deviations (RSD) were 11% for DSG3, 9% for VEGF-C and 14% for β-Tub. Similarly, assays 
were repeated over a span of five days to assess inter-day variation, RSD were 13% for DSG3, 
12% for VEGF-C and 17% for β-Tub. In addition, recoveries of biomarkers panel from spiked 
protein depleted cell lysates were estimated to assess the accuracy of the assay. Percent recoveries 
after subtracting signals from controls varied between 80% and 120% indicating accuracy of the 






Table 4.2. Spike-Recovery results for multiplexed biomarker proteins spiked in RIPA buffer 
with 5% human serum (n=4)  
 
Comparison of online and offline cell lysis. 4 different cell lines were used to challenge the 
performance of the developed assay to lyse cells online and quantify target biomarker proteins in 
the lysates. HN12, HN13, HN30 and Cal27 cell lines were lysed offline using a previously reported 
lysis protocol and target analytes were quantified in their lysates using the microfluidic chip. 
Results obtained from online lysis of the same cell lines were obtained and compared to the offline 
lysis results. Strong correlation between results obtained from both techniques demonstrated the 
efficiency of the online cell lysis protocol. In addition, cell samples were lysed using offline lysis 
protocol and target protein biomarkers were quantified in lysates using ELISA. Good agreement 







DSG3 12.5 11.8 (± 1.1) 94 (± 8) 
50 59 (± 4) 118 (± 8) 
100 111 (± 13) 111(± 13) 
VEGF-C 10 8.7 (± 1.5) 87 (± 15) 
40 34 (± 4) 85 (± 10) 
80 92 (± 11) 115 (± 14) 
Β-Tub 15 13 (± 2) 87 (± 13) 
45 43 (± 4) 95 (± 8) 
90 101 (± 11) 112 (±12) 




between results obtained by both techniques confirmed the accuracy of the developed microfluidic 
chip technology (Fig. 4.9).   
Fig. 4.9 Comparison of results obtained using online lysis, offline lysis and ELISA techniques for 
(A) HN12, (B) HN13, (C)HN30 and (D) CAL27 cell lines. (n=4) 
Single Cell Analysis 
In order to challenge assay sensitivity, cell cultures were diluted 1 million times to test the 
expression of the selected biomarker proteins in a single cell. 10 μL of the diluted samples 
(~Equivalent to single cell) were analyzed after an online lysis step and concentrations of the 
protein biomarkers were estimated. Due to cell-to cell variation and absence of cells in some 
diluted samples DSG3, VEGF-C and β-Tub expressions showed high degree of variation between 





Fig.  4.10 Estimated biomarker concentration from single cell lysates for (A) HN12, (B) HN13, 
(C) HN30, and (d) CAL27 cell lines. 3 different samples were tested from each cell line (n=2) to 
study cell to cell variation.    
4.5 Discussion 
This work is the first report of online human cell lysis coupled to ultrasensitive detection of 
panel of biomarkers to accurately assess lymph node metastasis encountered in most of head and 
neck cancer patients. Cell lysis was achieved using chemical lysis augmented by short 2s pulse of 
50 KHz ultrasonic wave. Ultrasonication was essential component since it helped mix the cells 




fully automated system setup eliminating the need to mix the cell samples with lysis buffer before 
initiating the assy.  
Biomarker panel was selected to fully assess the biopsy sample in order to get a full picture of 
the lymph node status before deciding upon dissection procedure. DSG3 was used as a positive 
biomarker exclusively expressed in invaded lymph nodes, and absent in non-invaded ones. The 
ability to detect sub-femtogram levels of DSG3 facilitated the discovery of as low as a single 
metastasized cell in the collected sample. VEGF-C has been previously reported to have strong 
correlation to state of head and neck cancer metastasis.48,49 Combining both VEGF-C and DSG3 
in the same assay would increase the significance of assay outcomes towards making an educated 
decision on the lymph node dissection.  
This work also reported for the first time the use of β-Tub as a marker to estimate the number 
of cells in each sample analyzed in a ligand-binding assay format. β-Tub has been used as loading 
control for western blots but has not been explored in ligand-binging assay format.50,5134,35 Ability 
to correlate found concentrations of each biomarker to the number of cells in the sample provide 
a more precise diagnostic significance.  
The use of chitosan hydrogel to immobilize antibodies provided a 3D platform for antibody-
antigen interaction improving the interaction kinetics which in turn was reflected in decrease in 
assay time and increased sensitivity. One component of this enhanced performance was the ability 
to immobilize approximately 2.0 x 1013 Ab/detection chamber. The other component was the 
expandable hydrogel nature of the chitosan layer that allowed the formation of water filled 




Excellent antibody surface coverage provided by chitosan hydrogel film improved the 
interaction kinetics between antigen flowed into detection compartment and antibodies on the chip 
surface. This improved kinetics was also supported by the microfluidic nature of the detection 
compartment with low volume/surface area ratio (10 μL/cm2). This helped accelerate diffusion-
controlled antigen-antibody interaction allowing reduction in assay time while maintaining ultra-
sensitivity. In addition, the use of polymeric streptavidin multi-labelled with up to 400 HRP 
enzmes allowed the huge signal amplification has resulted in the sub femtogram LOD. 
Chemiluminescence signals has been generated using ultra-sensitive substrate (West Femto® 
Luminol) with its enhanced luminescence characteristics allowing bright images at very low 
antigen concentrations.              
4.6 Conclusion 
An ultra-sensitive detection strategy for biomarkers extracted from single cells was developed and 
validated. The technique depends on a physicochemical on-chip lysis protocol that adapt mixing 
cells with lysis buffer using 50 KHz ultrasonic waves for 2s. 3D printed microfluidic chip was 
designed to run assay automatically with reagents and samples delivered to detection compartment 
using peristaltic micro-pumps controlled by Arduino microcontroller. Detection compartment had 
8 chambers that were massively coated with covalently immobilized capture antibodies on 
hydrogel chitosan film. Three protein biomarkers were tested in order to assess metastatic cancer 
cells in lymph nodes of Head and Neck Cancer (HNC) patients. Performance of the system was 
optimized to achieve sub-femtogram LOD of the selected biomarkers by applying signal 
amplification strategy using polymeric streptavidin Poly-HRP that resulted in LOD of 0.10 fg/mL 
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Influence of Antibody Immobilization Strategy on Carbon Electrode 
Immunoarrays 
5.1 Abstract     
We report here the influence of antibody immobilization strategy on protein immunosensors 
on screen printed carbon electrode arrays in terms of antibody binding activity, analytical 
sensitivity, limit of detection, and stability. Horseradish peroxidase (HRP) was the model analyte 
with anti-HRP immobilized on the sensors, and HRP activity was used for detection. Covalently 
immobilized anti-HRP antibodies on electrodes coated with chitosan, electrochemically reduced 
graphene oxide (rGO), and dense gold nanoparticle (AuNP) films had only 20-30% of the total 
immobilized antibodies active for binding. Active antibodies increased to 60% with passively 
adsorbed antibodies on bare electrodes, to 85 % with oriented antibodies using protein A 
covalently immobilized on AuNP-coated carbon electrode, and to 98% when attached to protein 
A passively adsorbed onto bare electrodes. Passively adsorbed antibodies on bare electrodes lost 
activity in 1-2 days, but antibodies immobilized using other strategies remained relatively stable 
after 5 days. Covalent immobilization gave limits of detection (LOD) of 40 fg mL-1, while 
passively adsorbed antibodies or protein A on carbon electrodes had LODs  4-8 fg mL-1, but were 
unstable. Sensitivity was highest for antibodies covalently attached to AuNP electrodes (2.40 
nA/log pg mL-1) that also had highest antibody coverage, and decreased slightly when protein A 
on AuNP was used to orient antibodies. Passively adsorbed antibodies and oriented antibodies on 
protein A gave slightly lower sensitivities. Immobilization strategy or antibody orientation did not 
have a significant effect on LOD, but dynamic range increased as the number of active antibodies 





5.2 Introduction  
Antibodies are major tools for ligand binding assays due to their ability to bind and target 
analytes in complex sample matrices with high selectivity and specificity.1 Immobilization of 
antibodies on a solid surface or nanoparticle is often a crucial step for developing sensors for target 
analytes. Immunoassay format has been adapted to a wide spectrum of diagnostic tests including 
enzyme linked immunosorbent assay (ELISA),2 protein microarrays,3 lateral flow assay (LFA),4 
radioimmunoassay (RIA),5 and electrochemical immunosensors.6,7 Performance is predicted to 
depend on the method of antibody immobilization that can control surface coverage, correct 
orientation of antibodies to bind analytes, degree of nonspecific binding, and sensor shelf life.8 
Electrochemical immunosensors are attractive due to inherent high sensitivity, simplicity of 
instrumentation, ease of integration into microfluidic systems, multiplexing capabilities, and 
possible upgrades to point-of-care (POC) devices.9,10 Microfluidic electrochemical 
immunosensors have been developed to detect target analytes in environmental samples,11 
biological fluids,12-14 and pharmaceutical preparations.15 In electrochemical immunosensors, 
antibodies are immobilized onto sensor electrodes of materials including metals,16, 17 conductive 
polymers 18 and different forms of carbon.19 Carbon electrodes are available at low cost and give 
excellent performance in sensors due to a wide range potential window, low resistance, and low 
residual currents.20-22 Screen printed electrodes have been widely used in sensor applications due 
to their relative low-cost mass production in single sensor or array format, and ease of design and 
miniaturization.23    
For antibody attachment, sensor electrodes have been modified with functionalized 




electrospray sputtering.27 Carbon nanotube forests were used on electrodes to immobilize 
increased amounts of antibodies on immunosensors resulting from high surface area of the 
nanostructured surface.28 
 Layer-by layer (LBL) assembly is a fast, facile technique for immobilizing polymers and 
nanomaterials on carbon electrodes. 29-31 Decorating carbon electrodes with a film of glutathione-
coated gold nanoparticles (AuNP) is an effective antibody immobilization strategy to construct 
ultrasensitive immunosensors that also yields a large population of antibodies on a nanostructured 
surface.32 Electrochemical deposition of graphene on electrodes from graphene oxide dispersions 
can also improve immunosensor performance.33 Passive adsorption of antibodies on carbon 
electrode surface is another approach that can been utilized.34, 35 Antibodies can also be oriented 
on electrodes through binding Fc region onto protein A letting Fab region free for antigen capture. 
Protein A is 42 KDa surface protein derived from Staphylococcus aureus bacteria and has five 
specific IgG binding domains.  
In this paper, we compare six different antibody immobilization techniques on screen printed 
carbon electrodes, namely, attachment to glutathione-AuNP layers, electrochemical deposition of 
reduced graphene oxide (rGO), chitosan films, passive antibody adsorption, passively adsorbed 
protein A oriented antibody immobilization and covalent immobilization of protein A on AuNP 
electrodes (Scheme 5.1). We utilized anti-horseradish peroxidase (anti-HRP) as a model antibody 
to quantify horseradish peroxidase (HRP) in calf serum as a human serum surrogate. 
Amperometric current was measured at -0.3 V against Ag/AgCl upon addition of H2O2 to activate 
HRP and hydroquinone (HQ) as mediator.28 Results were confirmed by measuring catalytic 
activity of captured HRP on sensor surfaces. Surface loading of antibody, sensitivity, limit of 




High sensitivity was achieved when large amounts of active antibodies were immobilized. A high 
degree of antibody orientation increased dynamic range, but was not a factor in LOD or sensitivity. 
 
 
5.3 Materials and methods 
Materials. All chemicals were of analytical grade and nanopure water was prepared using a 
Hydro® Picosystem®. Screen printed carbon electrodes featuring eight electrodes were from 
Kanichi®. Gold (III) chloride trihydrate (HAuCl4), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC), N-hydroxysulfosuccinimide sodium salt (NHSS), 
hydroquinone (HQ), hydrogen peroxide (30%), graphite powder (99%), potassium permanganate, 
poly(diallyldimethylammonium chloride) (PDDA, MW 100,00– 200,000, 20%) were from Sigma 
Aldrich®. Poly(dimethoxy)silane (PDMS) kit was from Dow Corning®. Phosphate buffer saline 
(PBS) pH 7.4 was 0.01 M sodium phosphate in 0.14 M NaCl, 2.7 mM KCl and phosphate buffer 
saline-tween20 (PBS-T20) was 0.01 M sodium phosphate in 0.14 M NaCl, 2.7 mM KCl and 0.5% 




Tween-20. SIGMAFAST® O-phenylenediamine (OPD) tablets and horseradish peroxidase (HRP) 
were from Sigma Aldrich®. Anti-horseradish peroxidase mouse monoclonal antibody (Ani-HRP) 
[2H11] (ab10183) and recombinant protein A (ab52953) were from Abcam®.   
Instrumentation: Microfluidic device incorporated a PDMS gasket with a flow channel in 
between two micromachined poly(methyl methacrylate) (PMMA) plates. The chamber is equipped 
with Pt counter electrode and Ag/AgCl reference electrode wires. A Kanichi® screen printed 
carbon electrode array featuring eight electrodes was inserted in the microfluidic chip under the 
PDMS flow channel. Amperometric measurements were done by applying -0.3V vs. Ag/AgCl 
using a multichannel CHI 1040 electrochemical workstation as reported previously in similar 
microfluidic arrays.,29,36(Fig. 5.1) while flowing a mixture of 100 μM H2O2 in 1 mM HQ in PBS 
buffer.     
Antibody concentration. A relatively high concentration of anti-HRP (100 µg/mL) was used 
in order to achieve maximum possible surface coverage in all tested strategies. Same concentration 
of antibodies was also used for different immobilization techniques to get a comprehensive 
comparison where the sensor performance will solely dependent on the immobilization technique 
and not the availability of antibodies. 
Layer-by-layer (LBL) electrode modification. LBL film growth was used for anti-HRP 
immobilization using alternating layers of PDDA and glutathione-gold nanoparticles (AuNP). As 
reported previously.32 Carboxylic acid groups on AuNP were activated by EDC/NHSS for 10 
minutes, rinsed with DI water and dried with nitrogen. Anti-HRP at 100 μg mL-1 was spotted onto 
sensors, and arrays were left overnight at 4˚ C.  Before use, arrays were washed with PBS-T20, 





Fig. 5.1 Immunoassay system: (A) syringe pump, injector for samples and standards; (B) 
assembled detection chamber consisting of 2 machined PMMA plates, top plate holds 
symmetrically placed reference Ag/AgCl 0.6 mm diameter and 0.2 mm platinum counter electrode 
wires along the entire length of the 8-sensor array. Peek tubing is fitted to connect inlet and outlet; 
(C) PDMS channel 2.8 x 0.15 x 1.0 cm, volume 60 µL, placed above sensors; (D) Kanichi screen-
printed carbon 8-sensor array alone. 
Electrochemical deposition of graphene oxide (rGO). The array was immersed in 4 mg/mL 
graphene oxide (GO) solution prepared using modified Hummer’s method 37 in 0.5 M lithium 
perchlorate. rGO was electrochemically deposited at -1.2 V vs. SCE for 60 s. Arrays were rinsed 
with water and dried with nitrogen. EDC-NHSS was used activate residual carboxylic groups on 




and arrays were left overnight at 4˚ C. Before use, arrays were washed with PBS-T20 and incubated 
with 1% BSA in PBS for 1 hr, and then rinsed with PBS-T20.  
Antibody immobilization on chitosan. A thin film of chitosan was formed on sensor 
electrodes by spotting 0.25 mg mL-1 of chitosan in 0.05 M hydrochloric acid (pH 4.5). After 1 hr 
incubation, arrays were dried under vacuum, and amine groups of chitosan were activated by 
spotting 3% glutaraldehyde in PBS (pH 7.8), incubated for 2 hr, washed with water and dried using 
nitrogen. Anti-HRP (100 μg mL-1) was spotted on the arrays and left overnight at 4˚ C, then rinsed 
with PBS-T20, incubated with 1% BSA for 1 hr and rinsed with PBS-T20 before use.  
Passive adsorption of antibodies. 100 μg mL-1 of anti-HRP antibodies were adsorbed on 
sensors by incubating overnight at 4˚ C.  Arrays were rinsed with PBS-T20, blocked with 1% BSA 
for 1 hr, and washed with PBS-T20 before use.  
Passively adsorbed protein A oriented antibody immobilization. 25 μg mL-1 protein A were 
spotted on bare electrodes and allowed to incubate overnight at 4˚ C. Arrays were rinsed with PBS-
T20 and incubated with 100 μg mL-1 anti-HRP for 3 hr, rinsed with PBS-T20, blocked with 1% 
BSA in PBS for 1 hr, and washed with PBS-T20 before use.  
Covalent immobilization of protein A on AuNP electrode for oriented antibody 
immobilization. LBL strategy was utilized to decorate electrode surface with AuNP, that was 
activated by incubation with EDC/NHSS for 10 minutes. Protein A (25 µg mL-1) was spotted and 
incubated on electrode surfaces overnight at 4˚C. Arrays were rinsed with PBS-T20, and incubated 
for 3 hr with 100 μg mL-1 anti-HRP, rinsed with PBS-T20, blocked with 1% BSA in PBS for 1 hr 




HRP assay. Arrays decorated with anti-HRP were inserted into the microfluidic chamber 
(Figure 5.1) where PBS buffer flowed at 100 μL min-1 flow rate using a syringe pump (New Era, 
NE-1000). 100 μL of standard or sample solution was loaded into the sample loop and injected 
using the sample injector (Rheodyne®, 9725i). Once the sample filled the microfluidic detection 
chamber, as determined by tests with dye solutions, flow was stopped and sample was incubated 
for 20 mins. Then, arrays were washed by flowing PBS-T20 for 3 min at 100 μL min-1. Flow was 
switched from PBS-T20 to 1 μM HQ mediator in PBS and amperometry was done at -0.3 V vs. 
Ag/AgCl while injecting 100 μL of 100 μM H2O2 in 1 mM HQ/PBS. 
Quantitation of antibodies immobilized on electrode surface. Bicinchoninic acid assay 
(BCA) was used to quantify the actual number of antibodies immobilized on the electrode surface 
38. Briefly, 100 μL micro BCA reagent kit (ThermoFisher® 23235) was prepared according to the 
vendor specification and incubated with 80 electrodes with immobilized antibodies at 37˚ C. BCA 
solution with the developed blue color was transferred to microplate and absorbance was measured 
at 562 nm. The concentration of immobilized anti-HRP was estimated utilizing a calibration graph 
constructed by running the same BCA procedures for series of standards of anti-HRP.  
Quantitation of active antibodies: In order to estimate the number of active antibodies 
immobilized on electrodes, increasing concentrations of HRP were allowed to incubate for 20 
minutes with electrodes and electrochemical oxidation catalyzed by HRP was measured. 
Hydroquinone was used as a mediator to shuttle electrons between electrode surface and enzyme 
distant from the electrode surface.36  The use of mediator was essential to avoid variations of 
electrochemical signal resulting from varying distance between enzyme and electrode surface. 
Signal saturation was considered as the point where all active antibodies captured HRP molecules 




saturation point was equivalent to the concentration of active antibodies immobilized on electrode 
surface.   
HRP activity. Arrays decorated with anti-HRP captured HRP from solution using excess 
amount HRP (50 ng mL-1) for 20 min. Each array was then washed with PBS-T20 and incubated 
with 100 μL of 4 mg mL-1 O-phenylenediamine (OPD) substrate in 0.05 M phosphate-citrate buffer 
(pH 5.0). OPD is converted to colored product (2,3–diaminophenazine) and the solution was 
transferred to a micro-well plate and absorbance measured at 492 nm after stopping reaction with 
25 μL 3M HCL.39 Concentration of HRP on electrodes was estimated using a calibration made 
with standard HRP solutions and the same protocol.  
Inter-day assays. Electrodes were prepared, blocked, rinsed with PBS-T20 and stored in PBS 
buffer at 4˚ C for up to 5 days, the tested with 5 pg mL-1 HRP over 5 days. Results were used to 
estimate the loss of the immobilized antibody activity.      
5.4 Results  
Nominal electrode surface area and antibody coverage. Sensor surface area was estimated 
before and after surface modifications. Electrochemically active surface area of the bare electrode 
was estimated at 9.5±0.5 x10-4 cm2, using the slope of cyclic voltammogram (CV) peak currents 
vs.  square root of the scan rate (ѵ1/2) for 0.5 mM ferrocene methanol (Fc-MeOH, D: diffusion 
coefficient of Fc-MeOH in TEAP = 7 X 10-6 cm2 s-1)40 in 0.1 M tetra-ethyl ammonium perchlorate 
(TEAP, Fig. 5.2).41 Surface area after modification with rGO and was 2.1±0.1 x10-3 cm2, and for 
AuNP 2.4±0.2 x 10-3 cm2, while chitosan electrodes had area 9.1±0.3 x10-4 cm2. Surface areas 
were used to compute the theoretical monolayer coverage of antibodies using antibody dimensions 




Protein A is a 42 kDa polypeptide with two functionally distinct halves, A C-terminal half for 
binding to cell walls and an N-terminal half for IgG binding. The protein binding portion is 
composed of five semi-identical, three-helix bundles, i. e. Ab-binding domains (E-D-A-B-C) that 
are interconnected with highly flexible linkers.44 Average dimensions of protein A are 25-30 nm,45 
so theoretical maximum surface coverage of protein A was 1.2 x 108 – 1.5 x 108 on bare electrodes 
and 2.7 x 108 - 3.2 x 108 on AuNP electrodes. Although protein A has five antibody binding sites, 
actual binding of antibodies per protein A molecule is been estimated at 2.46 Theoretical numbers 
of antibodies were also estimated for binding onto protein A on electrodes (Table 5.1).    
Fig. 5.2 Electrode surface area studies before and after electrode modifications using 0.5 mM Fc-
MeOH in 0.1 M TEAP vs Ag/AgCl (0.14M NaCl); (A) Cyclic voltammograms at different scan 
rates (from 10 to 200 mV/s) for bare electrode; (B) peak current (Ip) vs. square root of the scan rate 
(1/2 )for bare electrode; (C) Ip vs. 
1/2 for rGO coated electrode; (D) Ip vs. 
1/2 for AuNP electrode; 
(E) Ip vs. 




Actual antibody coverage. BCA assays were used to measure the actual number of bound 
antibodies on the electrode (Table 5.1). Surprisingly, chitosan electrodes had antibody coverage 
higher than the theoretically estimated coverage since it had 1.4±0.1 x 10-3 μg anti-HRP/electrode 
equivalent to 6.1±0.6 x 109 anti-HRP/electrode, this was about 3 times higher coverage than the 
theoretical value, probably because of the 3 dimensional chitosan hydrogen forms with an area 
larger than that of the electrode.47 Protein A immobilized on AuNP electrodes had approximately 
10 times higher number of antibodies compared to the theoretical estimation based on calculated 
electrochemical active surface area of the modified electrodes, as flexible anchoring of protein A 
on a dense film of AuNP on electrode surface provided an excellent platform to covalently 
immobilize protein A that had the flexibility to bind to up to 6.1 ± 0.4 x 109 anti-HRP/electrode. 
Passively adsorbed Protein A had a much smaller number of immobilized anti-HRP.  
Table 5.3. Actual antibody coverage from BCA assay and theoretical estimated antibody coverage 




Coverage/electrode x 109 Coverage found x 109  
(Side-on) (end-on) 
AuNP/(EDC/NHSS) 1.90 7.10  6.2± 0.3 
rGO/(EDC/NHSS) 1.70  6.20  4.3±0.3 
Chitosan/Glutaraldehyde 0.73  2.40 6.1±0.6  
Direct antibody Adsorption 0.76 2.70  1.1±0.03  
Protein A (Passive Adsorption) 0.24  0.30 0.26±0.01  





Active Antibodies. The saturation level of HRP signals in the arrays where signals level off, 
was used to estimate the number of active antibodies. Bulk HRP concentration at each saturation 
point was used to estimate the maximum number of HRP molecules that can interact with 
antibodies on electrode surface during incubation. Number of HRP molecules that would bind to 
antibodies immobilized on each electrode, from the volume of solution inside microfluidic 
chamber, was estimated using Einstein’s diffusion equation (Eq. 1) assuming that binding is 
diffusion controlled.48 For diffusion coefficient (D) of HRP 5 x 10-7 cm2 s-1,49 the distance travelled 
by HRP in 20 min incubation time is 0.012 mm.  
𝑑 =  √(2 𝐷 𝑡)  …………………………………………………………. (1)  
where d is distance in cm, D is the diffusion coefficient, and t is time in sec.  
The solution containing HRP available to bind to anti-HRP immobilized on each electrode is a 
hemisphere of radius 0.012 mm with volume 7.24 x 10-6 μL (Fig. 5.3).  
Fig. 5.3 Schematic illustration of the diffusion-controlled interaction between antigen and 
antibodies immobilized on electrode surface; maximum distance that can be travelled by antigen 
with diffusion coefficient of 5 x 10-7 cm2/s in 20 min was estimated to be 0.012 mm. This result in 




The number of HRP molecules in this available volume of solution to bind anti-HRP was estimated 
from the saturation concentrations (Table 5.2 and Table 5.3). Amounts of actively binding 
antibodies were relatively low except for those using an initial layer of protein A, which had 85% 
active antibodies for AuNP electrodes and 98% on bare carbon (Fig. 5.4)  
Active antibodies on each electrode was also measured using the HRP enzyme activity assay 
for oxidaton of O-phenylenediamine (OPD). Enzymes captured on sensor arrays were incubated 
with OPD for 1 hr and color developed was used to estimate the number of HRP molecules that 
correspond to the number of active anti-HRP. Calibration using soluble HRP with was used to 
esimate the concenterations of HRP on arrays (Fig. 5.5). Good agreement between results obtained 
from electrochemical and OPD assays was found (Table 5.2).  
Table 5.4. Active antibodies/electrode using different immobilization strategies on screen printed 
carbon electrode estimated using electrochemical assay and OPD enzyme activity assay (standard 




No. of Active antibodies/electrode x 109 
Electrochem. estimate  OPD Assay  
AuNP/(EDC/NHSS) 2.56±0.20
  2.94±0.11 
rGO/(EDC/NHSS) 1.28±0.14  1.48±0.13  
Chitosan/Glutaraldehyde 1.28±0.09  1.00±0.05  
Direct antibody Adsorption 2.56±0.08  2.11±0.11 
Protein A (Passive Adsorption) 0.26±0.01  0.23±0.01  





Fig. 5.4 Calibration for different anti-HRP immobilization strategies; (A) Example showing 
amperometric peaks with increasing concentrations of HRP using antibodies (Ab) passively 
adsorbed on bare carbon. Calibration graphs: (B) passively adsorbed Ab on bare electrodes; (C) 
covalently immobilized Ab on AuNP electrodes; (D) covalently immobilized Ab on rGO 
electrodes; (E) covalently immobilized on chitosan electrodes; (F) Ab oriented onto protein A 
passively adsorbed on bare electrodes; (G) Ab oriented onto protein A covalently immobilized on 
AuNP electrode. Logarithmic fits shown as blue dashed line; arrows indicate saturation points 





Table 5.3. Theoretical calculation of no. of HRP available to bind to anti-HRP immobilized on 
electrodes at each concentration of HRP standards under diffusion control 
[HRP]  
(pg mL-1) 
[HRP] available to bind anti-
HRP/electrode (pg mL-1) 
No. of HRP available to bind anti-
HRP/electrode 
0.008 5.79 x 10-15 8.20 x 104 
0.04 2.90 x 10-14 4.10E x 105 
0.2 1.45 x 10-13 2.05 x 106 
1 7.24 x 10-13 1.03 x 107 
5 3.62 x 10-12 5.13 x 107 
25 1.81 x10-11 2.56 x 108 
125 9.05 x 10-11 1.28 x 109 
250 1.81 x 10-10 2.56 x 109 
500 3.62 x 10-10 5.13 x 109 











Fig. 5.5 Calibration curve of series of standard HRP using SIGMAFAST OPD assay. 100 μL O-
phenylenediamine (4 mg/mL) in 0.05 M phosphate-citrate buffer (pH 5.0) was incubated with 100 
μL of HRP standard for 1 hour, reaction was stopped using 25 μL 3M HCL and absorbance was 
measured at 492 nm. Error bars represent standard deviation, n=3.   
 
Electrode to electrode variation. Selected concentrations of HRP were assayed on different 
electrode arrays on the same day to estimate intra-day signal variations for each immobilization 




immobilization using passively adsorbed protein A gave relative standard deviation (RSD) less 
than ±5%. For covalent attachment, RSDs were ±11%, for rGo electrodes, ±8% for AuNP, and 7% 
for chitosan and oriented antibodies on protein A covalently immobilized on AuNP (Fig. 5.6). 
Fig. 5.6 Inter-day electrode to electrode variation showing amperometric peaks obtained from 5 
different electrodes challenged against 5 pg mL-1 HRP; anti-HRP antibodies (A) passively 
adsorbed on bare electrodes; (B) covalently bound to AuNP decorated electrodes; (C) covalently 
bound to rGO coated electrodes; (D) covalently bound to chitosan modified electrodes; (E) 
oriented on protein A passively adsorbed on bare electrodes; (F) Anti-HRP oriented on protein A 
covalently immobilized on AuNP decorated electrodes. Insets are columns representing peak 




Stability. Arrays were challenged with the same concentration of HRP over 5 days. Chitosan 
coated electrodes showed the best stability with only a small loss in signal over 5 days (≤ 7%). 
Electrodes with passively adsorbed antibodies were the fastest to deteriorate with 15-20% loss of 
activity each day in the first 3 days. AuNP and rGO electrodes were relatively stable for the first 
three days of storage (~5% decrease/day) followed by larger decrease in signal in 5th day of storage 
(~10%). Antibodies adsorbed on protein A electrodes had good stability over the test period with 
approximately 20% decrease in the overall signal after 5 days (Fig. 5.7, Table 5.4). 
Fig. 5.7 Stability of electrodes as a function of change of the electrochemical amperometric signal 
challenged against 5 pg mL-1 HRP over a period of 5 days; Anti-HRP antibodies were (A) 
Passively adsorbed on bare electrodes; (B) Covalently immobilized on AuNP decorated electrodes; 
(C) Covalently immobilized on rGO coated electrodes; (D) Covalently immobilized on chitosan 
modified electrodes; (E) Oriented onto protein A passively adsorbed on bare electrodes; (F) 
Oriented onto protein A covalently immobilized on AuNP decorated electrodes. Insets are 




Table 5.4. Comparison of performance for HRP sensors using different antibody immobilization 

















after 5 days 
storage   
Anti-HRP/AuNP 
40 40 fg mL-1 
250 pg mL-1 
2.40 6.2 ± 0.3 
 
21% ≤ 30% 
Anti-HRP/rGO 
 
40 40 fg mL-1 
125 pg mL-1 
0.55 4.3 ± 0.3 
 
30% ≤ 35% 
Anti-
HRP/Chitosan 
40 40 fg mL-1 
125 pg mL-1 
0.90 6.1 ± 0.6 21% 
 
≤ 7%  
Anti-HRP/Protein 
A /AuNP  
40 40 fg mL-1 
500 pg mL-1 
2.01 6.1 ± 0.4 
 
85% ≤ 20 
Anti-HRP/bare 
electrode  
4 8 fg mL-1 
250 pg mL-1 
1.75 1.1 ±0.03 60% > 60% 
Anti-HRP/Protein 
A/bare electrode 
8 8 fg mL-1  
25 pg mL-1 
1.62 0.26 ± 0.1 
 
98% ≤ 25 
   
5.5 Discussion  
Results above demonstrate the influence of antibody immobilization strategy and coatings on 
screen-printed carbon electrode for immunoarrays. Sufficient binding activity and availability of 
antibodies immobilized on sensor electrodes is a key factor for sensor performance, we found that 
other factors such as stability, degree of antibody coverage, orientation, and assay to assay 




A) can extend the dynamic range, but have little influence on sensitivity or LOD, most easily seen 
by comparing AuNP-electrodes with Protein A/AuNP (Table 5.4). This goes against the common 
view that improving antibody orientation also improves sensitivity and LOD of immunoassays.7,8 
Sensors with 20-30% orientation (Table 5.4) still have enough active antibodies to achieve good 
sensitivity and LOD in the lower concentration range, and had AuNP electrodes with 21% active 
antibodies had the best sensitivity. This result agrees with our earlier study of sensors coated with 
upright single-wall carbon nanotube forests having large antibody coverage, but ~30% active 
antibodies.50 These sensors had excellent sensitivity and LODs for prostate specific antigen and 
interlukin-6 proteins in serum. For sensors with 85-95% correct antibody orientation, the main 
effect is maintenance of sensitivity in the higher concentration range because more of the 
antibodies are being active, and that extends dynamic range upward. We believe these conclusions 
are dependent on sizes of both antibodies and antigens. 
Antibody coverage was highest when antibodies were bound to protein A/AuNP films 
electrodes (Table 5.4), although these sensors did not have the best sensitivities. In addition, 
nanostructured dense 5 nm AuNP packing32 and the chitosan hydrogel property both extend the 
surface area available for Ab binding, leading to the binding of more antibodies. Electrodes with 
passively adsorbed antibodies showed the highest LODs (Table 5.4), but  were the least stable 
(Table 3), Instability can be attributed to documented hydrophobic interactions between antibodies 
and electrode which lead to denaturation and loss of binding activity.51 The hydrogel nature of 
chitosan causes antibody-chitosan matrix swelling in aqueous solution to more than 600% of its 
original mass.47 The hydrogel provides high water content that also helps preserve antibody 




rGO coated electrodes may have mixed affinities toward antibodies through covalent binding 
to residual carboxylic groups after electrochemical deposition and hydrophobic adsorption to 
graphene. This explains the intermediate antibody activity (30%), that lies between covalent 
immobilization and passive adsorption, of rGO coated sensors. Sensitivities and LODs of sensors 
with covalently immobilized antibodies were similar with LOD 40 fg mL-1 for chitosan modified, 
rGO coated and AuNP electrodes (Table 3). Wider dynamic range achieved by AuNP sensors 
compared to other covalent immobilization techniques can be attributed to high surface coverage 
of antibodies compared to other sensors. Although chitosan modified electrodes had surface 
antibody coverage similar to AuNP films, its narrower dynamic range is due to a degree of electron 
transfer blockage by the chitosan (Table 5.2).  
Protein A passively adsorbed on the sensors preserved 98% of immobilized antibody activity, 
and maintained up to 80% of sensor activity after 5 days storage, but had the worst dynamic range 
(Table 5.4). This is presumably due to low surface coverage of antibodies, about 10% of that of 
the other sensors. This was overcome by covalent immobilization of protein A onto AuNP 
electrodes, which offers flexible anchoring and allowed a large increase in antibody coverage 
while maintaining 85% activity.  
5.6 Conclusions  
Results show that ability of the immunosensors to achieve high sensitivity is mainly a function 
of having sufficient active antibodies immobilized and the degree of surface coverage. Protein A 
mediated antibody surface conjugation that allowed oriented immobilization of antibodies 
preserved 98% of antibody activity, but was outperformed by other sensors possessed higher 
surface coverage (Table 5.4). In general, a high degree of antibody orientation on AuNP sensor 




findings suggest that increasing the number of antibodies on sensors by increasing electrode 
surface area is key factor to improve sensitivity. In addition, stable covalent conjugation of 
antibodies protects them from hydrophobic interaction-induced denaturation found in passive 
adsorption. 
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